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1 Summary 
Type 1 diabetes is an autoimmune disease that leads to the destruction of insulin-producing 
pancreatic beta cells and consequently to hyperglycemia. In the last 60 years, the prevalence 
of type 1 diabetes has been increasing constantly and is predicted to continue rising. About 
80% of the disease risk is attributable to the genetic variation. Thanks to genome wide 
association studies the number of known disease-associated polymorphisms climbed from 
five to 53 in the last 10 years.  
As these studies reveal possible candidate genes but not underlying mechanisms we strove to 
take the next step and explore the association of two genes suggested by these studies with 
type 1 diabetes. 
As a method of choice we decided to use lentiviral RNAi in non obese diabetic (NOD) mice, 
a widely-used model for type 1 diabetes, introducing a shRNA directed against the target 
message into the genome of this mouse strain via a lentivirus. This allowed us to study the 
partial loss-of-function of the target gene within the context of diabetes, directly seeing its 
effect on autoimmune mechanisms. 
 
In this thesis we examined two different genes in this manner, Ctla4 and Clec16a. 
A type 1 diabetes associated polymorphism in the CTLA4 gene had been found to alter the 
splicing ratio of its variants soluble CTLA-4 (sCTLA-4) and full length CTLA-4, the 
associated allele producing less sCTLA-4 than the protective allele. We mimicked this effect 
by specifically targeting the sCtla4 mRNA via lentiviral RNAi in the NOD model. As a result 
we could confirm the reduction of sCTLA-4 to accelerate type 1 diabetes development. 
Furthermore we could show a function of sCTLA-4 in regulatory T cells, more specifically at 
least partly in their ability to modulate costimulation by antigen presenting cells.  
 
The second candidate gene, Clec16a was targeted with the shRNA in a way that was designed 
to knock down most splice variants. As the gene function and the effect of the associated 
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polymorphism was unknown, we reasoned this method to be feasible to investigate its role in 
type 1 diabetes. The knockdown of Clec16a in NOD mice resulted in an almost complete 
protection from diabetes development that could be attributed to T cells dysfunction. 
However, as expression patterns and a study of the Drospophila orthologue suggested a 
possible role of CLEC16A in antigen presentation we also examined antigen presenting cells 
in the thymus and periphery. Although we did not detect any effect of the knockdown on 
peripheral antigen presenting cells, thymic epithelial cells were clearly affected by the loss of 
CLEC16A, rendering them more activated and shifting the ratio of cortical to medullary 
epithelial cells in favor of cortical cells. We therefore suggest a role of CLEC16A in the 
selection of T cells, that needs, however, to be further investigated. 
 
In this thesis we provided a feasible and fast method to study function of genes and even of 
single splice variants within the NOD mouse model. We demonstrate its usefulness on two 
candidate genes associated with type 1 diabetes by confirming and unraveling the cause of 
their connection to the disease.  
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2 Zusammenfassung 
Typ 1 Diabetes ist eine Autoimmunerkrankung, bei der es zur Zerstörung von pankreatischen 
beta-Zellen und daraus folgend zu einer Hyperglykämie kommt. In den letzten 60 Jahren stieg 
die Diabetes Prävalenz stetig an und Studien sagen voraus, dass sich dieser Trend in Zukunft 
noch stärker fortsetzen wird. Man geht davon aus, dass ca. 80% des Erkrankungsrisikos für 
autoimmunen Diabetes genetischer Natur sind. Dank Genom-weiter Assoziationsstudien 
wurde dieser Beitrag gerade in den letzten zehn Jahren immer weiter aufgeklärt und bis heute 
wurden 53 mit Typ 1 Diabetes assozierte Polymorphismen identifiziert.  
Da diese Studien es nur leisten können, mögliche Kandidatengene aufzuzeigen, allerdings 
keine Aussagen über die zugrunde liegenden Krankheitsmechanismen machen können, haben 
wir es uns zum Ziel gesetzt diesen nächsten Schritt zu gehen und zwei der durch diese 
Studien vorgeschlagenen Gene auf ihre Rolle in der Typ 1 Diabetes Ätiologie zu untersuchen. 
 
Unsere Methode der Wahl war die lentivirale RNA Interferenz im Mausmodell der nonobese 
diabetic mouse (NOD).  Via lentiviralen Vektoren wird die Information für eine shRNA, die 
an die mRNA des Zielgenes bindet, in das Empfängergenom integriert. Die daraus folgende 
Herabregulierung der Ziel-mRNA erlaubt es uns den Effekt dieser fehlenden Geninformation 
auf die Immunregulation zu analysieren. 
 
Auf diese Weise wurden in dieser Thesis zwei Kandidatengene untersucht, Ctla4 und 
Clec16a. 
Der mit Typ 1 Diabetes assoziierte Polymorphismus im CTLA4 Gen verursacht eine 
Verschiebung im Splice Verhältnis der beiden Isoformen im Menschen, soluble CTLA-4 
(sCTLA-4) und full length CTLA-4, zu Gunsten der full length Variante. Im NOD  
Mausmodell konnte diese Verschiebung durch eine Einführung einer gegen sCtla4 
gerichteten shRNA nachgeahmt werden. In Folge dessen konnten wir bestätigen, dass eine 
Reduzierung der sCTLA-4 Variante die Typ 1 Diabetes Entwicklung beschleunigt. Zudem 
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konnten wir eine Rolle von sCTLA-4 in der Funktion von regulatorischen T Zellen, genauer 
in deren Fähigkeit die Kostimulation durch Antigen präsentierenden Zellen zu modulieren,  
zeigen. 
 
Bei dem zweiten Gen, das in dieser Thesis untersucht wurde handelte sich um Clec16a. Es 
wurde von einer shRNA herunterreguliert, die den Großteil der Varianten abdeckt, da die 
Funktion des Genes, sowie die Auswirkungen des assoziierten Polymorphismus unbekannt 
waren.  Der Knockdown von Clec16a in der NOD Maus verursachte einen fast vollständigen 
Schutz vor Diabetes, der im weiteren Verlauf den T Zellen zugerechnet werden konnte. 
Allerdings hatten das Expressionsmuster, sowie eine Studie am Drosophila Ortholog ema eine 
Rolle von CLEC16A in Antigen präsentierenden Zellen impliziert. Folglich untersuchten wir 
die Möglichkeit, dass diese Zellgruppe in der Peripherie oder im Thymus durch den 
CLEC16A Mangel beeinträchtigt sein könnten. Tatsächlich wies die Zellgruppe, die im 
Thymus für die Selektion von T Zellen zuständig ist einen erhöhten Aktivierungsstatus auf, 
was auf eine modifizierte T Zell Selektion hindeuten könnte. 
 
Mit dieser Arbeit konnten wir eine praktikable und schnelle Methode, für die funktionelle 
Analyse von Genen und sogar einzelnen Splice Varianten, aufzeigen. Wir konnten ihren 
Nutzen weiterhin an zwei mit Typ 1 Diabetes assoziierten Kandidatengenen unter Beweis 
stellen, indem wir so die Assoziation bestätigen und Licht auf die zugrunde liegenden 
Mechanismen werfen konnten.  
INTRODUCTION 
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3 Introduction 
3.1 Immune Regulation 
In order to protect the body from pathogens, the immune system has to recognize a vast 
variety of chemical structures, like proteins and peptides, lipids and carbohydrates.  
There are two branches of the immune system, with different spectra of recognition. The one 
mainly responsible for the fist line of defense possesses a large but still limited and invariant 
receptor repertoire. It is called the innate immunity. On the other hand there is the adaptive 
immunity with cells exhibiting an enormous array of specificities, with every cell having its 
very own antigen receptor1.  
 
Two mechanisms are contributing to the huge receptor repertoire of B and T lymphocytes, 
which are the main cell types of the adaptive immunity.  
First they undergo a process called V(D)J- recombination, during which the different 
segments of the  B cell or T cell receptor, V (variable), D (diversity), J (joining) and C 
(constant) are combined in a unique way for every cell. This somatic recombination happens 
during B and T cell development in the central lymphoid organs, bone marrow or thymus 
respectively.  
B cells additionally undergo a second round of receptor editing in the periphery, lymph nodes 
and spleen, called somatic hypermutation.  
 
In case of T cells the theoretical number of different receptors produced by somatic 
recombination is 1018 2.  Since they are generated in a random process, a considerable number 
(20-50%3-6) of these receptors are not functional or have a potentially harmful affinity for 
self-antigens. Nevertheless “only” 3-8% of the population suffers from autoimmunity7, 
indicating that there are strategies to hold these self-reactive cells in check. These strategies 
are described in the following sections for T cells. 
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3.1.1 Central tolerance and T cell development  
The first step of control takes place during T cell development in the thymus. Here T cells 
with inoperative TCR or with high self-affinity die selectively8. These processes are called 
positive and negative selection respectively and contribute to central tolerance.  
 
The progenitors for T cells, like those for B cells, are hematopoetic stem cells (HSCs) and 
arise in the bone marrow. Whether these are the cells that migrate directly into the thymus or 
whether the cells entering the thymus are other downstream progenitors is not clear yet. Still 
it was suggested that many progenitors are able to contribute to the T cell lineage if exposed 
to Notch signaling in a hematopoetic environment9,10.  
  
The progenitors enter the thymus in the corticomedullary junction and migrate to the 
subcapsular zone11,12 where they proliferate extensively13. As earliest progenitors in the 
thymus several distinct populations were described, of which the double negative (DN1) 
subsets a and b (CD3- CD8- CD4- CD44+ c-kithi CD25+ and lo) showed the most substantial 
proliferation and best potential as precursor for T cell lineage14. They differentiate into DN2 
cells (Linlo CD44+ c-kithi CD25+) and then DN3 cells (Linlo CD44lo c-kitlo CD25+), while 
migrating from entry sites to the inner cortex11,12. The latter are already committed to the T 
cell lineage and undergo somatic recombination of TCRβ or δ and γ loci, depending on 
whether they are determined to the α/β- or γ/δ-T cell fate15. Cells of the α/β-T lineage form a 
pre-TCR after successful β-chain rearrangement, rescuing them from cell death16. 
After having passed the checkpoint of beta-selection by effective pre-TCR signaling, the cells 
undergo extensive proliferation and differentiate into double positive (DP; CD4+CD8+) T 
cells17. Now the α-locus is subject to rearrangement, resulting in α/β-TCR-expression. From 
that point on all following checkpoints are based on interactions of the α/β-TCR with self 
peptide/MHC (pMHC) ligands on stromal cells in the thymus18.  
INTRODUCTION 
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3.1.1.1 Positive Selection 
The first of these points of control is called positive selection and takes place in the thymical 
cortex, with cortical epithelial cells (cTECs) being the major antigen presenting cells. During 
this process, a survival signal is delivered exclusively for cells having rearranged a functional 
TCR that is able to recognize self-peptides bound to self MHC with an intermediate 
affinity19,20.  Not until then is the α-chain rearrangement terminated, allowing not yet selected 
DP thymocytes to change their specificities during their 3-4 d lifespan, thereby increasing 
their chances to receive a positive signal in the end21.  But despite this, and though the TCR 
seems to be prone to recognize MHC6,22, around 90-95% of DP thymocytes die a death of 
neglect23,24.  
To date only little is known about the selecting peptide-MHC repertoire presented by cTECs 
in vivo (reviewed in ref. 25).  However it has been indicated that a complex pMHC repertoire 
leads to a broad positively selected T cell repertoire26,27, even if the single peptides are only 
present with low abundance28. Also there have been reports that identified pathways to 
generate peptide-MHC complexes in cTECs that are not applied in other thymic or peripheral 
APCs (reviewed in 25). 
Cathepsins are lysosomal proteases responsible for the degradation of the invariant chain of 
MHC class II molecules. Moreover they are able to generate MHC ligands from proteins in 
the lysosome28. In contrast to mTECs and peripheral APCs, cTECs use cathepsin L instead of 
cathepsin S, suggesting the generation of a different set of peptides due to the usage of a 
different protease (evaluated in 25). Indeed a role of cathepsin L in positive selection of CD4 T 
cells could be shown by silencing the gene coding for this protease, resulting in a 60-80% 
reduction of the CD4 SP compartment29.  
Further evidence for a distinct pMHC repertoire in cTECs arose from the identification of a 
cTEC specific gene, Prss16, coding for the thymus specific serine protease30,31. Its exact role 
in the pathway of MHC ligand repertoire shaping is as yet unclear, its restriction to 
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endosomal and lysosomal compartments however points to a role in the proteolytic generation 
of MHCII peptides. Unlike cathepsin L, knockout of Prss16 does not have a striking effect on 
the CD4 SP compartment32, it does however alter the abundance of single TCR specificities33. 
This may also be the reason why PRSS16 displays association with type 1 diabetes34. 
TECs highly express MHCII but are unproductive in presenting exogenous antigens via the 
endocytic pathway35,36. Instead they exhibit an exceptionally high constitutional 
macroautophagy activity, especially in the cortex, that allows them to present self-antigens on 
MHCII37,38. Macroautophagy, in general a mechanism that provides new resources in the case 
of starvation, is a process in which part of the cytoplasm and /or organelles is enclosed in a 
double membrane of about 1µm diameter that eventually merges with endosomes and 
lysosomes, thereby degrading its content and making it available for reuse39-41. It thus 
represents a further pathway by which cTECs are able to present unique pMHC complexes to 
developing thymocytes. 
All aforementioned cTEC mechanisms can largely be attributed to the MHCII pathway, 
however these cells also feature unique MHCI loading processes. As sole cell subset they 
employ the subunit β5t in their proteasome, thereby forming a thymoproteasome42. It is a 
variation of the immunoproteasome of APCs and mTECs, that differs from the conventional 
proteasome by replacement of some β subunits allowing them to produce peptides optimized 
for MHCI binding42,43. It had been suggested that the thymoproteasome lowers the affinity of 
the peptides for MHCI and makes the binding less stable25,44. Knockout of the gene coding for 
β5t, Psmb11, reduces the CD8SP compartment by impaired positive selection of certain TCR 
specificities and renders them less active45. 
Taken together all these unique ways to produce MHC ligands point to a unique set of 
peptides presented by cTECs and establishing positive selection. At least part of the necessity 
for different ligands being presented by cTECs and mTECs/DCs could be attributed to the 
prevention of a reencounter of the same peptides in the medulla, thereby causing a higher 
signal and negative selection25. However this theory would have to be reconciled with the 
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postulated vital tonic homeostatic signal provided by T cells facing the same low affinity 
pMHC complexes on peripheral APCs as previously in the cortex46,47.  
3.1.1.2 Negative Selection 
Eventually, positively selected thymocytes migrate to the medullary part of the thymus. Here 
they are subject to negative selection during their 4-5 day passage25, a process purging the 
thymocytes of potentially dangerous auto-reactive cells. During this process about 50-70% of 
positively selected thymocytes are reckoned to die48-50. They do so after high affinity contact 
to medullary thymic epithelial cells (mTECs) or thymic dendritic cells18. This TCR signal 
results in activation of apoptotic signal transduction pathways, presumably including the 
MINK/p38/JNK, MINK/Bim/Bcl-2 and ERK5/Nur77 pathways51.  
Among this large number of negatively selected thymocytes, there are however not only 
thymus-specific T cells but also cells with TCRs recognizing peripheral self-antigens. 
Already in 1989, it had been assumed that genes from different peripheral tissues are 
expressed in the thymus, thus allowing the negative selection of those harmful thymocytes52. 
In 2001, the expression of those tissue restricted antigens (TRAs) was seen to be a unique 
feature of mTECs53. Moreover TRAs in the thymus were found to be not only spatially but 
also temporally restricted54, and their genes to be highly clustered in the genome, suggesting a 
contribution of epigenetic mechanisms to regulation of their expression18. Furthermore the 
promiscuous gene expression (pGE) of TRAs by mTECs is at least partly regulated by the 
autoimmune regulator (Aire)55, though the mechanism of this regulation remains elusive. 
TRAs can also be presented by thymic DCs56, in a process called cross-presentation, after 
having taken up mTEC derived antigens57 in a yet undefined manner (reviewed in 58 ). 
In 2008 Aire expression was also detected in stromally derived cells in secondary lymphoid 
organs, also expressing TRAs and thus likely extending the deletional tolerance to the 
periphery59-61. 
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Also during their passage through the medulla, double positive thymocytes differentiate into 
single positive (CD4+ or CD8+) T cells. The lineage is dependent on whether the TCR is 
MHC I (CD8) or MHC II (CD4) restricted and is chosen during positive selection. 
 
3.1.2 Peripheral Tolerance and regulatory T cells 
In addition to recessive tolerance, provided by intrinsic processes like apoptosis due to 
negative selection in the thymus and anergy of T cells chronically stimulated by pMHC 
without costimulation, there is also a way to dominantly suppress auto-reactive T cells in the 
periphery. This extrinsic mechanism is to the current knowledge carried out by Foxp3-
expressing regulatory T cells (Tregs)62. Also Foxp3 negative Tr163 and Th364-66 cells have 
been shown to act suppressive especially in the intestine, conveying oral tolerance, however 
will not be discussed further in this thesis. 
 
First evidence for the existence of Tregs was given after neonatal thymectomy (nTx) studies 
by Nishizuka and Sakaguchi, revealing a regulatory cell population generated in the neonatal 
thymus on day three67-69. This finding laid the foundation for further characterization of that 
population. In 1996, it was found that transfer of CD25+ CD4+ T cells can rescue neonatal 
thymectomized mice from their normally autoimmune phenotype69. Later the more specific 
marker Foxp3 was identified during studies on the genetic contribution to the human 
autoimmune disorder IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-
linked) and the mouse mutant scurfy70-73. Loss of function of that X-chromosome encoded 
forkhead transcription factor leads to fatal lymphoproliferative immune mediated disease. 
Together with its high and stable expression in regulatory CD25+ CD4+ T cells (Treg cells) 
and its requirement for their differentiation and function this led to its declaration as marker 
number one for Treg cells74-79 . 
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3.1.2.1 Treg development 
There are two types of Foxp3 positive regulatory T cells: thymus derived Treg cells, also 
called natural Treg cells (nTreg cells) and adaptive Treg cells (iTreg cells), which are induced 
from naïve CD4 T cells in the periphery. But although they can be clearly differentiated due 
to their development and TCR specificity, the actual differences in their field of function 
remain elusive80. 
 
Natural Treg cells develop along with other T cell subsets in the thymus. The triggers that 
lead to differentiation into the Treg lineage are still highly controversial. At present three 
different models are discussed: 
 
The instructive model assumes that the strength of the TCR-signal determines Treg 
differentiation. As already described, low affinity for self causes death by neglect due to lack 
of positive selection. Too high an affinity causes apoptosis through negative selection. It was 
proposed that a slightly lower affinity for self would be responsible for Treg formation.   
Support for this model came from studies on CD4/ CD8 lineage decision mechanisms81,82, 
activation marker expression on Tregs as sign for a strong TCR signal62 , and Treg TCR 
repertoire analysis, that showed only partially overlapping83-85 specificities with conventional 
T cells that were also more self-affine 85. 
These observations were supported experimentally by showing the necessity of endogenous 
TCR-rearrangement for development of nTreg cells in TCR transgenic mice86. Yet later it was 
found that coexpression of the cognate antigen can rescue Treg development in TCR 
transgenic mice which lack endogenous TCR rearrangement87-89.  
 
However negative selection was significantly increased in these studies, supporting a 
stochastic-selective model, in which self-reactive Foxp3 expressing Treg precursors 
selectively survive in the thymus rather than being “instructed” to express Foxp390. In line 
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with that finding, molecules that support survival and attenuate TCR signaling, like CTLA-4, 
display an increased expression in a Foxp3-dependent fashion 62. 
 
An extension of the instructive model is the two-step model. This model hypothesizes a 
second signal additional to TCR signaling, since there is evidence that the TCR signal alone is 
not sufficient to cause Foxp3 upregulation and thus Treg cell lineage commitment: For 
instance it is possible that Treg and non-Treg cells express the same TCR with increased 
reactivity for self91. Furthermore only some thymocytes in mice with transgenic TCR and 
coexpression of cognate antigen become Treg cells, others turn into anergic non-Treg 
cells87,89.  
One essential second factor for Treg development was found to be IL292. Two other common 
gamma-chain cytokines IL7 and IL15 can also contribute to the Treg cell fate decision but 
have a weaker impact93. 
 
Adaptive regulatory T cells are in contrast to nTregs generated in the periphery from naïve T 
helper cells under divers circumstances. However the basic requirements for Foxp3 
upregulation in vitro as well as in vivo could be identified to be TCR stimulation plus 
presence of TGFβ and IL-294. Under these conditions the Foxp3 enhancer element is bound 
by a cooperation of STAT3 and NFAT62,80.  IL-2 additionally induces STAT5 that could also 
drive Foxp3 expression95. Also unlike  nTregs, iTregs require the upregulation of CTLA-4 for 
their differentiation from naïve Th cells96. 
As aforementioned, iTregs develop in multiple microenvironments that are to date not fully 
understood. So, they are found in the GALT (gut-associated lymphoid tissue) to convey oral 
tolerance97,98 and as a reaction to microbiota and food antigens99. In addition they were seen to 
arise in chronically allergic inflamed tissues100 and in reaction to tumor101 and 
transplantation102.  
 
INTRODUCTION 
 21 
Recently a potential marker to distinguish nTregs and iTregs was suggested to be Helios, a 
member of the Ikaros transcription factor family only expressed by thymic derived Foxp3+ 
Tregs103. This study also gave first insight into the importance of iTregs, as they amounted to 
30% of Foxp3+ cells in the periphery.  
 
3.1.2.2 Mechanisms of Treg function 
Natural as well as induced regulatory T cells exhibit multiple processes through which they 
suppress conventional T cells in vitro. Still despite all these candidate molecules and 
pathways found through different approaches in vitro, it is still unclear which or if any of 
these, are applied in vivo104.  
 
Most of the classic in vitro suppression assays include antigen presenting cells (APCs: 
irradiated spleen cells or non-irradiated dendritic cells) and soluble anti-CD3 to stimulate T 
cells. Others excluded APCs completely and included bead- or plate-bound CD3 and CD28 
antibodies instead. It was shown that although the absence of APCs reduced the suppressive 
activity of Treg cells, both CD4/CD8 T cells but also in particular APCs can be cellular 
targets for Treg-mediated suppression104,105. 
As for targeting of conventional T cells, several studies have shown that Treg cells mediate 
the inhibition of cytokine expression, especially IL2106,107. It was also claimed that Treg cells 
might act on conventional T cells by competing with them for IL2 with their high affinity 
receptor (CD25, CD122, CD132), thereby causing Bim dependent apoptosis of the 
effectors108. However some studies disagree and explain the IL2 deprivation by consumption 
through contaminating activated conventional T cells in Treg preparations (both 
CD4+CD25+)104,109.  
Though it was demonstrated that Treg cells fail to suppress conventional T cells when 
separated from them by a semipermeable membrane, cytokine mediated suppression was 
suggested to be still possible if cell-cell-contact is involved106,110. Recently Collison and 
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colleagues showed that only the induction of suppression and not the Treg function as such is 
cell contact dependent in vitro111. They showed that cell contact with conventional T cells 
induces expression of IL35, a novel inhibitory cytokine112 and IL10, which then are able to 
mediate suppression of T cells across a semipermeable membrane. Another candidate for 
inhibition through secreted molecules is galectin-1 a member of the family of beta-galactoside 
binding proteins, which could induce cell cycle arrest, apoptosis and inhibition of 
proinflammatory cytokine production after binding113. 
A further possibility for Treg cells to act on conventional T cells is direct cytolysis. Under 
certain circumstances they can turn into “cytotoxic suppressor” cells and lyse target cells via 
granzyme B, perforin or Fas-FasL interaction104,114,115. 
 
Since it is a crucial task of Treg cells to suppress priming and differentiation of effector T 
cells in vivo and in vitro, the APC is an important target.  
One of the means to target them is the cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is 
constitutively expressed on Treg cells and interacts with the costimulators CD80 and CD86 
on APCs. This interaction was seen to be able to cause downregulation of the expression of 
these costimulators in mouse and human DC in vitro116-118. The function of CTLA-4 in Treg 
cells was further elucidated by a recent study of Wing and colleagues119. They specifically 
deleted CTLA-4 in Treg cells and could show that the deficiency in this one cell type alone is 
sufficient to cause fatal lymphoproliferative disease. Their explanation is the impaired 
suppressive ability of these cells, in particular in their ability to downregulate CD80/86 on 
DCs. A possible mechanism by which this downregulation could be explained is trans-
endocytosis during which Tregs take up surface molecules from APCs in the immunological 
synapse and that are degraded subsequently120,121. Additionally interaction of CTLA-4 with 
CD80/86 has been claimed to induce indoleamine 2,3-dioxygenase (IDO), a potent regulatory 
molecule, expression in DCs122.  
Other molecules thought to be involved in APC regulation by Treg cells are LAG-3 
(lymphocyte activation gene 3)123, a CD4 like molecule binding MHCII with high affinity, 
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CD39124, an ectoenzyme hydrolyzing ATP thereby inactivating extracellular ATP an indicator 
of tissue destruction and the fibrinogen-like protein 2 (FLG2)125, which was also shown to be 
able to reduce CD80/86 expression on DCs. 
 
All in all the immune system developed, along with its astounding repertoire to recognize 
foreign antigens, several effective regulatory pathways to prevent this large repertoire from 
harming the own body. But still as already mentioned, autoimmune disorders are one of the 
most common diseases with 3-8% incidence and more than 60 different known disorders 
(Deutsche Gesellschaft für Autoimmunerkrankungen e.V.), meaning that there are also 
multiple pitfalls where the control can fail. 
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3.2 Type 1 Diabetes 
One of the many different autoimmune disorders is type 1 diabetes, a disease caused by the 
destruction of insulin producing beta cells in the pancreatic islets of Langerhans126. The cells 
held mainly responsible for the destruction are auto-reactive cytotoxic T cells. They infiltrate 
the islets together with other leukocytes in the first stage of disease, called insulitis127. The 
second stage, overt diabetes is seen when about 80% of the beta cells have been destroyed. 
The remaining cells cannot produce enough insulin to provide for a proper regulation of blood 
glucose level, resulting in hyperglycaemia.127 In the course of the disease this can lead to 
severe symptoms like ketoacidosis, kidney failure, heart disease, stroke or blindness128. Onset 
of disease typically happens in the youth, but also adult forms of disease development are 
possible. Since the 1920s diabetes has been treated by administration of exogenous insulin, so 
that the ultimate shortening of life expectancy was decreased to about 10 years128.  
 
There is still controversy about how beta cell antigens are initially exposed to APCs, which 
can then present them to auto-reactive T cells. One theory is physiological cell death, since a 
wave of beta cell death can be observed in young rodents at 14-17 days of life and also 
perinatally in humans127. But also the contribution of viruses, especially the coxsackivirus, to 
onset of diabetes has been widely discussed129. However, incidence in animal models of type 
1 diabetes is highest under germ-free conditions, arguing against the requirement of an 
environmental trigger for disease onset130. Interestingly, coxsackivirus infection only 
triggered diabetes in NOD mice with already preexisting insulitis131-133, suggesting that a 
similar scenario could be true for humans.  
Somehow peptides from beta cells themselves or peptides mimicking them are subsequently 
presented to CD4 and CD8 T cells in the islets, draining lymph nodes or even at distant sites. 
There, T cells specific for antigens derived from insulin, glutamic acid decarboxylase, 
tyrosine phosphatase 1A-2 and 1A-2ß and possibly other proteins are getting activated. 
Through activation they gain the ability to migrate into the islets, where they reencounter 
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their antigen and induce beta cell death either under direct T cell/beta cell contact or as a 
bystander effect after T cell/APC contact127. B cells are proposed to act mainly as antigen 
presenting cells in type 1 diabetes etiology134, as autoantibodies whose occurrence can be 
leveraged for early diagnosis are most likely not pathogenic135.  
The correlation between failing regulatory mechanisms and pathogenesis of T1D is summed 
up in figure 1: 
 
Figure 1:  Correlation of control mechanisms of the immune system and T1D; from 
Ounissi-Benkalha and Polychronakos, 2008136 
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Over the second half of the twentieth century the incidence of type 1 diabetes has been 
increasing rapidly. Predictions estimate a 40% rise of incidence in children under 15 years of 
age from 2005 to 2020, with the largest increase of about even 70% in children under the age 
of 5137. Although the phenomenon of increasing incidence is seen worldwide there are vast 
geographical differences. While there are 40 new cases of type 1 diabetes per 100.000 
inhabitants per year in Finland, only 0.1 new onsets per 100.000 occur in Asia and South 
America, representing the two extremes of a north-south divide138. 
 
Type 1 Diabetes develops as a result of a combination of environmental and genetic factors. 
The environment is assessed to contribute approximately 20% of overall disease risk 139. Over 
40 genetic loci have been identified to associate with Type 1 diabetes and many of them also 
with other autoimmune diseases140. 
The most important susceptibility locus is the HLA region on chromosome 6p21.3. Its 
variants determine the way peptides are presented to the immune system via MHC and it 
contributes to about 50% to the genetic susceptibility of T1D141-145. To date it is agreed that 
the major susceptibility markers for T1D are HLA class II DQB1*0302 on the DR4 haplotype 
and DQB1*0201 on the DR3 haplotype136. 
 
Figure 2:  Odd ratios for susceptibility alleles of selected T1D-associated loci; Mehers 
and Gillespie 146 adapted from Todd et al.143 
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Polymorphisms in the insulin (INS), PTPN22, CD25, PTPN2, CLEC16A (KIAA0350), 
CTLA4, IFIH1 genes also contribute to T1D susceptibility, albeit to a lesser extent. This 
thesis focuses on the role of CTLA4 and CLEC16A in T1D, thus only they will be addressed 
in more detail, as it would go beyond the scope of this report to elaborate on all candidate 
genes. 
3.2.1 CTLA-4 and Type 1 Diabetes 
CTLA4 was shown to be associated with several autoimmune disorders, including type 1 
diabetes147. Here the association was attributed to a single nucleotide polymorphism (SNP) in 
the 3’ UTR (CT60). Depending on which allele of that polymorphism one carries, the 
susceptibility to T1D becomes higher (G allele) or lower (A allele). This polymorphism 
affects expression levels of a particular splice isoform of CTLA-4: the soluble CTLA-4 
(sCTLA-4). Its mRNA expression is already reduced in the heterozygous state and is least 
with homozygous susceptibility allele148. 
CTLA-4 is encoded by 4 exons and is expressed in two different isoforms in humans: the full 
length form, consisting of all 4 exons and the soluble form, lacking the exon coding for the 
transmembrane domain (exon 3). 
 
Figure 3: Splice isoforms of CTLA-4 in humans 
 
As already described in section 3.1.2.2 CTLA-4 plays an important regulatory role in the 
immune system and is expressed in Treg cells and activated conventional T cells. Some of the 
processes that CTLA-4 is proposed to be involved in are also mentioned in section 3.1.2.2. So 
far, no information is available as to which extent the two isoforms contribute to the 
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regulatory function, but the complete knockout of CTLA-4 in mice results in a massive 
lymphoproliferative disorder.  
3.2.2 CLEC16A and Type 1 Diabetes 
Association of the genetic locus on chromosome 16 in the region of CLEC16A (KIAA0350) 
with type 1 diabetes was found later than CTLA4 in a genome-wide association study carried 
out by The Wellcome Trust Case Control Consortium in 2007149. This region was further 
validated by several follow up studies142,143,150-154  and eventually also claimed to be associated 
with other autoimmune diseases like primary adrenal insuffiency155, multiple sclerosis154,156,157 
and crohn´s disease158. 
In humans CLEC16A, a gene that spans over 237kb, is alternatively spliced into 14 variants, 
only half of them coding for proteins between 1053aa to 118 aa of length 
(www.ensembl.org). SNPs found to be associated with different diseases are all intronic and 
so far no alteration of regulatory elements by them has been revealed (www.emsembl.org). 
However transcription ratios of two variants in the thymus have been found to be altered by 
SNP rs12708716 that was previously shown to be associated to T1D and MS159.  
The function of CLEC16A is still unknown, but its nearly exclusive expression in immune 
cells indicates a function in immune processes (biogps.org). Computational analysis further 
identified a putative ITAM143 (immunoreceptor tyrosine-based activation motif), 
transmembrane domain (www.ch.embnet.org) and a proposed C-type lectin domain151 in the 
human protein that is however disrupted in all other orthologues (prosite.expasy.org).  
Recently a study on abnormal synaptic overgrowth and protein trafficking at the 
neuromuscular junction of Drosophila melanogaster revealed a role of the CLEC16A 
orthologue ema in endosomal maturation and function160. The authors of this study further 
showed that this effect was partly due to ema’s role in abrogating BMP signaling in the 
endosomes. Notably they were successful in rescuing the phenotype of the ema mutant by 
introducing human CLEC16A, thereby showing that the essential function of ema is highly 
conserved in its orthologues. This is also supported by the presence of highly conserved 
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CLEC16A orthologues from mouse to Zebrafish, Xenopus, C. elegans and Arabidopis (160 and 
www.ensembl.org). Strikingly no orthologue is present in Yeast, suggesting a role for 
CLEC16A in multicellularity160. 
3.2.3 Non obese diabetic (NOD) mice as model organism 
The non obese diabetic (NOD) mouse strain was developed in 1980 emerging from the 
Jcl:ICR outbred strain161,162. NOD mice spontaneously develop autoimmune diabetes between 
three and six months of age163. The disease incidence is gender specific and lies around 60-
80% in females and 20-30% in males162,164, probably due to an estrogen induced Th1 skewing 
of immune responses165. However both time of onset and incidence are intrinsic to each 
individual animal housing facility163. In NODs the course of diabetes is commenced by non-
destructive insulitis with infiltrating macrophages and dendritc cells and subsequently also B 
and T cells166. The infiltrating T cells finally destroy beta cells and the disease thus progresses 
to overt diabetes, finally even forming tertiary lymphoid structures at the site of 
inflammation167. 
In spite of this more aggressive course of diabetes, NOD mice otherwise develop a disease 
that shares a lot of characteristics with human type 1 diabetes, like the presence of 
autoantibodies and auto-reactive CD4 and CD8 T cells. Since the genetic linkage to the 
disease is also comparable to that in human patients168, this strain is an extremely suitable 
model to study T1D and has been used in an extensive number of studies so far. 
 
3.3 Lentiviral RNAi 
As aforementioned, genome wide association studies (GWAS) have already revealed 53 loci 
associated with type 1 diabetes (www.t1dbase.org). The information that can be drawn from 
these studies does however not point out specific unequivocally responsible genes, it rather 
results in one or more candidate genes possibly influenced by the associated SNP, especially 
since these are often found in non-coding regions169. Determining these genes and the 
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underlying pathways responsible for T1D incidence though is crucial to further understand 
etiology and thus ultimately improve treatment.  
As SNPs in most cases have a moderate effect170 and only seldom completely abrogate gene 
expression, knockout (KO), albeit being an effective method to assess the basic gene function, 
is often a too crass an approach to elucidate the effect of the polymorphism in disease. Also, 
until recently it was hardly feasible to generate a KO on the NOD background, due to the lack 
of ES cells171 and the problem of introducing foreign flanking DNA in the process of 
backcrossing172.  
A more flexible and physiological approach to find the pathway behind an association is RNA 
interference (RNAi). 
3.3.1 RNAi 
RNA interference regulates gene expression post-transcriptionally. On the prerequisite of 
sequence complementarity of short RNAs with target mRNAs, the target gene function is 
silenced by ablation of translation or degradation of the mRNA. RNAi is a highly conserved 
mechanism in eukaryotes, that was initially detected in C.elegans in 1991173 and attributed to 
dsRNA in 1998174 by Andrew Fire and Craig Mello, who were honored with the nobel prize 
for medicine / physiology in 2006 for this discovery.  
Endogenous microRNAs (miRNAs) of 22 nucleotides length or exogenous small interfering 
RNAs (siRNAs) are analogically generated from precursors by nuclear (Drosha)175,176 and 
cytoplasmic (Dicer)177 RNases. Mature mi- and siRNAs then associate with the RNA-induced 
silencing complex (RISC), a protein complex of the argonaute-family178,179. Only the guide 
strand, determined by its thermodynamically more instable 5’ end, remains in the complex, 
the passenger strand being degraded180-182. The manner of silencing is subsequently defined 
by the degree of complementarity of the guide strand with the target mRNA. A perfect match, 
mostly the case with siRNAs, leads to degradation of the target mRNA by Ago2. Mismatches 
in the binding, more common with miRNAs, lead instead to inhibition of translation183. 
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Even with the experimental application of siRNAs, a complete loss of expression of the target 
mRNA is unlikely. It rather leads to a diminished amount of expressed protein, a knockdown 
(KD), thereby providing the possibility to tune the expression in a more physiological manner 
than with the KO technology. 
3.3.2 Lentiviral trangenesis 
By establishing DNA-coded shRNAs184 and the possibility of them being carried by retro- or 
more specific lentiviruses185,186, it became practicable to generate animal models with 
constitutive or also induced RNAi. Plasmids coding for small hairpin RNAs (shRNAs) are 
introduced in modified, replication-deficient, lentiviral particles that allow the integration of a 
long terminal repeat (LTR) flanked DNA sequence into the host genome. By infecting single 
cell embryos of mice with this virus, the integrated DNA and thus the DNA coding for the 
shRNA is passed along into every cell of the animal, including the germ line. ShRNAs are 
recognized by Drosha and Dicer in the host cells and thus processed into siRNAs, mediating 
stable RNAi that is passed on to the progeny. 
This very fast and straightforward approach however also involves some difficulties. 
Although the degradation of mRNA is only possible on the prerequisite of perfect 
complementarity, unspecific effects could be due to impaired translation of non-targets187. 
Thus controls with a second shRNA are needed if applicable to compass these specific off-
target effects and to exclude effects caused by the integration. Also nonspecific off-target 
effects were described, as long dsRNAs activate the anti-virus response in cells and can also 
have other toxic effects. However shRNAs have been shown to be less immunogenic than 
siRNAs, since they are generated by the endogenous processing machinery188.  
As lentiviral transgenesis is not integration site-specific, the so-called position-effect 
variegation has to be taken into account. Depending on the site of integration, the overall 
expression and the expression in distinct cell subsets can vary considerably189.  
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Still the advantages of this method for our purpose to analyze candidate genes in the NOD 
mouse model outweigh these pitfalls, that can be addressed by carefully applying controls, 
and give us the possibility to explore the pathways behind the T1D associated 
polymorphisms.  
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4 Aims 
4.1 Functional study of sCTLA-4 in type 1 diabetes 
One susceptibility gene of human T1D is CTLA4. The susceptibility allele reduces the 
expression of sCTLA-4. Using lentiviral gene transfer, we are targeting the splice isoform 
sCTLA-4 specifically in NOD mice by RNAi and thereby mimicking the human 
susceptibility locus in these mice. This will give us the opportunity to explore the outcome of 
reduced sCTLA-4 on the development of T1D and the role of sCTLA-4 in the immune 
system in general. 
 
4.2 Functional study of CLEC16A in type 1 diabetes 
Not much is known about CLEC16A except that it is associated to several autoimmune 
diseases and it is expressed in immune cells, including DCs, B cells and natural killer cells. 
Again by the use of lentiviral RNAi we aim to downregulate the mRNA expression of that 
gene to be able to study its function in the NOD background. 
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5 Material 
5.1 Antibodies 
5.1.1 Cell culture 
Antigen Clone Concentration Supplier 
CD16/32 (FcgR3/2) 93 1 mg/ml eBioscience 
CD28 37.51 1 mg/ml eBioscience 
CD3ε 145-2C11 0,5 mg/ml eBioscience 
CD40 HM40-3 0,2 mg/ml eBioscience 
IgM eB121-15F9 0,5 mg/ml eBioscience 
 
5.1.2 Flow Cytometry 
Antigen Fluorochrome Clone Dilution Supplier 
Annexin V APC  1:100 BD 
Annexin V PE  1:100 BD 
B220 (CD45R) APC RA3-6B2 1:300 BD 
B220 (CD45R) PE RA3-6B2 1:300 BD 
B220 (CD45R) APC eFluor 780 RA3-6B2 1:400 eBioscience 
CD11b PE MI/70  BD 
CD11b PECy7 MI/70 1:800 BD 
CD11b eFluor 450 MI/70 1:1600 eBioscience 
CD11c APC HL3 1:300 BD 
CD11c PECy7 HL3 1:1600 BD 
CD11c eFluor 450 N418 1:200 eBioscience 
CD16/32 
(FcgR3/2) 
APC 93  eBioscience 
CD19 eFluor 450 1D3 1:1600 eBioscience 
CD25 Biotin 7D4  BD 
CD25 PECy7 PC61  BD 
CD25 PerCP-Cy5.5 PC61  BioLegend 
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CD25 APC PC61.5  eBioscience 
CD25 PerCP-Cy5.5 PC61.5 1:300 eBioscience 
CD3ε FITC 145-2C11  BD 
CD3ε PE 145-2C11 1:300 BD 
CD3ε PerCP 145-2C11 1:200 BD 
CD3ε V500 500A2 1:800 BD 
CD3ε PerCP-Cy5.5 145-2C11  BioLegend 
CD3ε Brilliant Violet 421 145-2C11  BioLegend 
CD4 Alexa 647 RM-4-5  BD 
CD4 APC-Cy7 GK1.5 1:800 BD 
CD4 PerCP-Cy5.5 RM4-5 1:800 BD 
CD4 V500 RM4-5 1:1600 BD 
CD4 Brilliant Violet 421 GK1.5  BioLegend 
CD4 APC RM4-5 1:800 eBioscience 
CD40L (CD154) PE MR1  BD 
CD44 PECy5 IM7 1:3000 BD 
CD45 eFluor 450    
CD45RB PE C363.16A 1:1600 eBioscience 
CD5 PE 53-7.3 1:300 BD 
CD62L FITC MEL-14  BD 
CD62L PE MEL-14 1:200 BD 
CD62L APC-Cy7 MEL-14  BioLegend 
CD69 PECy7 H1.2F3 1:300 eBioscience 
CD80 Biotin 16-10A1  BD 
CD80 APC 16-10A1 1:1600 eBioscience 
CD86 Biotin GL1  BD 
CD86 APC GL1 1:1600 eBioscience 
CD86 PE GL1 1:1600 eBioscience 
CD8α APC 53-6.7 1:800 BD 
CD8α PE 53-6.7 1:800 BD 
CD8α PECy7 53-6.7 1:800 BD 
CD8α eFluor 450 53-6.7 1:1600 eBioscience 
CTLA-4 (CD152) PE UC10-4F10-11 
Intra- 
cellular:1µg 
BD 
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CTLA-4 (CD152) PE UC10-4B9 
Intra- 
cellular:1µg 
eBioscience 
EpCAM PE-Cy7 G8.8 1:3200 eBioscience 
F4/80 PECy5 BM8 1:400 eBioscience 
F4/80 APC BM8  eBioscience 
Foxp3 APC FJK-16s  eBioscience 
Foxp3 PE FJK-16s  eBioscience 
GITR APC DTA-1 1:300 eBioscience 
GITR-L Biotin eBio YGL386  eBioscience 
Gr-1 (Ly 6G/C) PE RB6-8C5  BD 
IgD PE 11-26c.2a  BD 
IgM PE-Cy7 R6-60.2 1:200 BD 
Ly51 (BP-1) PE 6C3 1:800 eBioscience 
PI Purified/FG  
1µl/ 1x106 
cells 
BD 
RT1B (I-Ag7) PerCP OX-6 1:800 BD 
SA APC   BD 
SA PE   BD 
SA PerCP-Cy5.5   BD 
TCR Vβ 8.3 PE 8C1 1:50 BioLegend 
TCR Vβ11 PE RR3-15 1:100 BioLegend 
TCR Vβ12 PE MR11-1 1:400 BioLegend 
TCR Vβ13 PE MR12-4 1:50 BioLegend 
TCR Vβ2 PE B20.6 1:50 BioLegend 
TCR Vβ5.1, 5.2 PE MR9-4 1:400 BioLegend 
TCR Vβ6 PE RR4-7 1:100 BioLegend 
TCR Vβ7 PE TR310 1:100 BioLegend 
TCR Vβ8.1, 8.2 PE KJ16-133.18 1:100 BioLegend 
TCR Vβ9 PE MR10-2 1:400 BioLegend 
TCRβ APC H57-597 1:300 BD 
TCRβ Biotin H57-597  BD 
TCRβ APC eFluor 780 H57-597  eBioscience 
TCRβ PerCP-Cy5.5 H57-597 1:300 eBioscience 
Zap70 pY319 Alexa 647 17A/P-ZAP70  BD 
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5.1.3 Western Blot 
Antigen Conjugated Dilution Host Supplier 
CLEC16A no 1:1000 rabbit 
Provided by Lucy Davison, 
Lab John Todd, Cambridge, 
UK 
Rabbit IgG HRP 1:2000 goat Santa Cruz 
Biotin HRP 1:3000  New England Biolabs 
Tubulin no 1:1000 rat abcam 
Rat IgG HRP 1:3000 donkey Jackson ImmunoResearch 
 
5.2 Biological Material 
5.2.1 Bacteria 
Species Strain Supplier 
E.coli DH5 alpha MAX Invitrogen 
E.coli Novablue Novagen 
E.coli TOP 10 Invitrogen 
5.2.2 Cell lines 
Cell line Properties Supplier Origin 
293 F fast growing 
293 FT 
Fast growing, transformed with SV40 
large T antigen, highly transfectable 
293 H better adherence 
5.2.3 Mouse lines 
Line Genotype Supplier 
C57BL/6 WT Charles River 
NOD WT Taconic 
NOD CLEC16A KD #3 
NOD sCTLA-4 KD 
were bred in house 
NOD.Idd5 WT Taconic 
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NOD.Idd5 sCTLA-4 KD were bred in house 
NOD.SCID WT Taconic 
 
5.3 Buffers and Media 
5.3.1 Bacteria Culture and DNA preparation 
LB Medium: 
• 10 g Trypton 
• 10 g Yeast Extract 
• 5 g Sodium Chloride 
ad 1 l dH2O 
adjust to pH 7,0 with NaOH 
for selection: add Ampicillin, final concentration 50µg/ml 
 
LB Agar for plates: 
• 8 g  Agar 
• 500 ml LB Medium 
for selecting plates: add Ampicillin, final concentration 100 µg/ml 
 
Buffers Mini Preparation: 
P1: 
• 50 mM Tris-HCL pH 8,0 
• 10 mM EDTA 
• 100 µg/ml RNase A 
in  dH2O 
 
P2: 
• 200 mM NaOH 
• 1%  (w/v) SDS 
in dH2O 
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P3: 
• 3 M Kalium-Acetat  
in dH2O 
adjust to pH 5,5 with acetic acid 
 
TAE (50x): 
• 242 g Tris 
• 57,1 ml  Acetic acid 
• 100 ml 0,5 M EDTA pH 8,0 
ad 1 l  dH2O 
 
DNA Sample Buffer (6x): 
• 0,25% Bromine Phenol Blue 
• 0,25% Xylene Blue 
• 30% Glycerol 
in  dH2O 
 
5.3.2 Cell culture 
293 HEK cell Medium: 
• 10% (v/v) Fetal calf serum (FCS, Invitrogen) 
• 2 mM L-Glutamin (Invitrogen) 
• 50 U / µg 
/ml 
Penicillin / Streptomycin (Invitrogen) 
in DMEM  (Dulbecco´s modified eagle´s medium, Invitrogen) 
 
Lymphocyte Medium RPMI10: 
• 10% (v/v) Fetal calf serum (FCS, Invitrogen) 
• 2 mM L-Glutamin (Invitrogen) 
• 50 U / µg 
/ml 
Penicillin / Streptomycin (Invitrogen) 
• 55 µM β-Mercaptoethanol (Invitrogen) 
• 10mM HEPES (Invitrogen) 1M 
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• 1 mM Sodium Pyrovate (Invitrogen) 
in RPMI1640  (Roswell Park Memorial Institute medium, Invitrogen) 
 
5.3.3 Cell seperation and flow cytometry 
ACK lysis buffer: 
• 8,29 g  NH4Cl 
• 1 g KHCO3 
• 37,3 mg Na2EDTA 
• 1 l  dH2O 
pH 7,2 – 7,4  
 
Annexin binding buffer: 
• 10 mM  HEPES 
• 150 mM  NaCl 
• 5 mM KCl 
• 1mM MgCl2 
• 1,8 mM CaCl2 
ad dH2O  
pH 7,4 (NaOH)  
 
Dynabead separation buffer: 
• 0,1% BSA 
• 2 mM  EDTA 
ad PBS pH 7,2  
filter sterile  
 
MACS buffer: 
• 0,5% FCS 
• 2 mM  EDTA 
ad PBS pH 7,2  
filter sterile  
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PBS.EDTA for blood collection: 
• 2 mM  EDTA 
ad PBS pH 7,2  
 
5.3.4 ELISA 
Wash solution for ELISA (PBS.Tween 0,05%) 
• 500 ml 10x PBS 
• 2,5 ml  Tween 20 
ad 5 l dH2O  
 
5.3.5 Western Blot 
Reagent Supplier 
Antioxidant Invitrogen 
MOPS Buffer Invitrogen 
NuPAGE LDS Buffer  Invitrogen 
RIPA Buffer  Sigma 
Protease Inhibitor Cocktail Sigma 
Sample Reducing Agent Invitrogen 
 
 
Transfer buffer: 
• 2,9 g Glycine 
• 5,8 g  Tris 
• 0,37 g SDS 
• 200 ml Methanol 
ad 1 l dH2O  
 
TBS.T: 
• 6,05 g Tris 
• 8,76 g  NaCl 
• 800 ml dH2O 
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Dissolve and adjust to pH 7,5 
• 500 µl Tween 20 (for 0,2% TBST) 
ad 1 l dH2O  
 
Blocking solution: 
• 5 g Milk powder (nonfat, dried) 
• 100 ml  0,2 % TBS.T 
 
5.4 Chemicals  
Chemical Supplier 
Acetic acid glacial  Roth 
Agar Roth 
Agarose NEEO Ultra Quality Roth 
Beta mercaptoethanol Roth 
BSA (Albumin Fraction V) Sigma 
CaCl2  Roth 
Chloroform Roth 
Cyclophosphamide monohydrate Sigma 
DMSO AppliChem 
dNTPs Fermentas 
Ethanol >99,5% and denatured Roth 
Ethidium bromide Roth 
EDTA Roth 
Glycerol Roth 
Glycine Roth 
HEPES Applichem 
Hydrochloric acid 37% Roth 
H3-thymidine Hartmann analytic 
Isofluran cp-pharma 
Isopropanol Roth 
Ionomycin Sigma 
KCl Roth 
KHCO3 Roth 
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Methanol Roth 
Milk powder (nonfat, dried) Applichem 
MgCl2 Roth 
NaCl Roth 
Na2EDTA Roth 
NaHCO3 Sigma 
Na2HPO4x2H2O Roth 
NaH2PO4xH2O Roth 
NaOH Roth 
NH4Cl Roth 
PFA reagent grade Sigma 
PMA Sigma 
SDS Roth 
Sodium azide Roth 
Tris Roth 
Tris-HCl Roth 
Tween20 Roth 
 
5.5 Consumable supplies 
Consumable Supplier 
Bis/Tris Polyacrylamide precast gels 
(NuPAGE®, 4-12%, 1mm x 10/15) 
Invitrogen 
Cell culture plates 96 well (Flat, U, V bottom) BD 
Cell culture plates 24 well BD 
Cell culture plates 6 well BD 
Cell culture plates 10 cm  BD 
Cell culture plates 15 cm  BD 
Cover slips Hartenstein 
Cryotubes Hartenstein 
Diastix Roche 
Filter mats PerkinElmer 
Filter sterile 0,45µm VWR 
Glass ware VWR 
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Glass slides Hartenstein 
Gloves VWR 
Injection Needles Hartenstein 
Magnets VWR 
Microseals for reaction plates Applied Biosystem 
Nitrocellulose BioRad 
Parafilm Pechiney 
Pipettes (5ml, 10ml, 25 ml) VWR 
Reaction plates 96 well white VWR  
Reaction plates 384 well clear optical Applied Biosystems 
Reaction tube 1, 5 ml Starlab 
Reaction tube 15ml / 50 ml BD 
Reaction tube round bottom BD 
Syringes  VWR 
Tips TipOne, Starlab 
Ultracentrifuge tubes Beckman 
Whatman paper VWR 
 
5.6 Enzymes 
5.6.1 DNA Enzymes 
All Enzymes were used with accompanying buffers: 
Enzyme Properties Supplier 
BamHI 
BsrGI 
Restriction Endonucleases Fermentas 
CIAP Phosphatase Fermentas 
DNase I Deoxyribonuclease I Invitrogen 
EcoRI 
KpnI 
NheI 
Fermentas 
PacI 
Restriction Endonucleases 
New England Biolabs 
Pfu 
Taq (Dreamtaq) 
DNA Polymerases 
Fermentas 
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T4 Ligase DNA Ligase 
XbaI 
XhoI 
Restriction Endonucleases 
 
 
5.6.2 Collagenases and Cell culture Reagents 
Reagent Properties Supplier 
Collagenase D Collagenase Roche 
Dispase I Collagenase Roche 
eFluor 670 Proliferation dye eBioscience 
FCS Fetal calf serum Invitrogen 
HEPES Cell medium supplement Invitrogen 
L-Glutamine Cell medium supplement Invitrogen 
Liberase 
Blendzyme II 
Collagenase Roche 
LPS Lipopolysaccharide Sigma 
Penicillin 
/Streptomycin 
Antibiotics Invitrogen 
Snarf Proliferation dye Invitrogen 
Sodium Pyrovate Cell medium supplement Invitrogen 
TGFβ Transforming growth factor  R&D 
Trypan Blue 
Stain 
Cell dye Invitrogen 
Trypsin Serine protease Invitrogen 
 
5.7 Equipment 
Device Supplier 
Agarose Gel chamber BioRad 
Beta counter MicroBeta2 PerkinElmer 
Bio Image Reader Mulitimage III Alpha Innotech 
Blotting Chamber BioRad 
Centrifuge MiniStar VWR 
Centrifuge 5810R Eppendorf 
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Centrifuge 5424 Eppendorf 
ELISA Reader  
FACS Aria II BD 
Flow Cytometer FACS Canto BD 
Freezer / Fridge Liebherr 
Freezer -80°C Hera Freeze Thermo 
Gel Imager Herolab 
Harvester PerkinElmer 
Heating plate Heidolph 
Hemacytometer Hartenstein 
Homogenizer Polytron Kinematica 
Incubator Bacteria Thermo Electron Corporation 
Incubator Cell culture Thermo Electron Corporation 
Laminar Flow Luft & Reinraumtechnik GmbH 
Luminometer bMG Labtech 
Microscope Axiovert 40CFC Zeiss 
Microwave Bomann 
pH Meter Mettler Toledo 
Photometer Implen 
Pipettes (P2, 10, 200, 1000) Gilson 
Pipetus Hirschmann Laborgeräte 
Power Supply Unit BioRad 
Protein Gel Chamber Mini Invitrogen 
Rocker Switch Heidolph 
Scale  Kern & Sohn GmbH 
Scale (special accuracy) Mettler Toledo 
Thermoblock Eppendorf 
Thermocycler PXE 0.2  Thermo Electron Corporation 
Thrmocycler (real time) Applied Biosystems 
Ultracentrifuge Beckman Coulter 
Vaccuum pump VWR 
Vortex Genie 2 Scientific industries 
Waterbath Julabo 
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5.8 Kits 
Kit Supplier 
Cytometric Bead Array Flex Sets  BD 
DNeasy blood and tissue kit Qiagen 
Dual luciferase system Promega 
Dynal CD8 isolation Kit Invitrogen 
Dynal  Invitrogen 
ECL Perkin Elmer 
FoxP3 staining kit eBioscience 
Gel purification kit Qiagen 
MACS Separation Kit CD4 
MACS Separation Kit CD4+ CD25+ 
MACS Separation Kit CD4+ CD62L+ 
MACS Separation Kit CD43 
MACS Separation Kit Pan T cells 
Miltenyi 
Maxiprep kit Qiagen 
PCR Purificatio Kit Qiagen 
RNeasy Kit Qiagen 
Transcriptor first strand DNA synthesis kit Roche 
Trizol Invitrogen 
Universal probe library (UPL) probes Roche 
Universal probe master mix (ROX) Roche 
 
5.9 Primer and shRNAs 
5.9.1 qPCR Primer 
Clec16a / UPL 7 
fwd:  5’-TGTCCACCTTGTACGTCATTTC-3’ 
rev:  5’-TGTACTCATCTTCAAACATGTCCA-3’ 
Clec16a / UPL 9 
fwd: 5’-AACAGATGATGTCTTGGATCTGAA-3’ 
MATERIAL 
 48 
rev: 5’-AACCGCTGGACCATACCAC-3’ 
GAPDH / UPL 9 
fwd: 5’-AGCTTGTCATCAACGGGAAG-3’ 
rev: 5’-TTTGATGTTAGTGGGGTCTCG-3’ 
5.9.2 shRNAs 
Target sequences : 
sCTLA-4: 
GCAGATTTATGTCATTGCTAAA 
Clec16a #1: 
CGTGGAGTATCTCATGATGGAT 
Clec16a#2: 
ATCTGGCTGTGTCATCAAGGAT 
Clec16a#3: 
AACCTTGTACGTCATTTCTATA 
 
Ordered shRNA oligo sequences: 
TGCTGTTGACAGTGAGCG–target sense –TAGTGAAGCCACAGATGTA –target 
antisense –TGCCTACTGCCTCGGA 
5.10 Software 
Software / Website Supplier / Web address 
Adobe Photoshop CS2 Adobe Systems Inc. 
ApE – A plasmid editor M.Wayne Davis 
Bio Gene Portal System Biogps.org 
Ensembl Genome Browser www.ensembl.org  
Expasy Prosite prosite.expasy.org 
FACS Diva BD 
FlowJo 9.2 Treestar Inc. 
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Mac OS X 10.5.8 Apple Inc. 
Microsoft Office 2004 for Mac Microsoft Corporation 
National Center for Biotechnology Information www.ncbi.nlm.nih.gov 
Prism Graph Pad 
TM pred – Prediction of Transmembrane Regions www.ch.embnet.org 
 
5.11 Standards 
Standard Supplier 
DNA ladder 1Kb plus Fermentas 
DNA ladder low range Fermentas 
See Blue Plus 2 Pre Stained Standard Invitrogen 
Biotinlyated Protein Ladder Detection Pack Cell Signaling 
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6 Methods 
6.1 Microbiological methods 
6.1.1 Liquid overnight culture 
For mini-preparations bacteria were grown overnight in 3ml LB-medium in a sterile Falcon 
Polypropylen tube. The LB-medium was supplemented with 50µg/ml Ampicillin. The 
medium was inoculated with a single bacteria colony picked from an LB/Amp-Agar-plate and 
grown in an incubator over night at 37°C and 220rpm. 
An overnight culture for maxi-preparations had a volume of 100ml LB/Amp-medium and was 
inoculated with 100-200µl of a 3ml starter-culture. The maxi-culture was also grown over 
night at 37°C with 220rpm.   
6.1.2 LB-Agar-Plates 
To select bacteria, which had been transformed with Ampicillin-resistance containing 
plasmids, 150µl bacteria-suspension were plated out on Ampicillin containing LB-Agar-
plates. The final-concentration of Ampicillin in the plates was 100µg/ml. 
6.1.3 Transformation 
Approximately 5-10 ng of ligated vector or plasmid stock for retransformation were added to 
competent cells. NovaBlue cells were used for cloning and DH5 or TOP10 for 
retransformation. After 20 minutes incubation on ice, the cells were subjected to a heat shock 
at 42°C for 90 seconds. They were plated out on LB/Amp Agarplates immediately after 
cooling down and adding 150µl LB-medium. 
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6.2 Molecular biological methods 
6.2.1 DNA precipitation 
In order to precipitate DNA, cations are added binding to the negatively charged pospho-
backbone. The cations are added as a salt to the solution. By exchanging the Water for 
Ethanol as a solvent the DNA precipitates as insoluble salt. 
Protocol: 
½ volume 6M NaCl was added to the DNA solution, shaken vigorously and incubated on ice 
for 10 minutes. Insoluble components were then spun down for 10 minutes at 5000g. The 
supernatant, containing the DNA was then transferred to a new tube, where 1,3 volumes 
isopropanol were added. The tube was inverted and then incubated for 15 minutes at room 
temperature. The DNA could then be spun down at maximum speed for 10 minutes. 
Supernatant was removed and the pellet left for air drying for about five minutes. Finally the 
pellet was reconstituted in sterile H2O. 
6.2.2 Agarose gel electrophoresis of DNA 
Ususally 1% Agarose (for separation of smaller fragments: 1,5 -2%) were dissolved in TAE 
buffer by boiling. 3 µl of ethidium bromide were added after the solution had cooled down for 
2 minutes. Before loading the DNA into the wells, it was mixed with a 6x loading dye 
containing bromphenol blue. The separation was usually conducted at 100 V. The DNA was 
observed on UV-light box. 
6.2.3 PCR (Polymerase chain reaction) 
6.2.3.1 Standard PCR 
By polymerase chain reaction specific DNA fragments can be amplified. Both DNA strands 
are firstly denatured to allow specific oligonucleotides (primer) to anneal to their 
corresponding sequence. Emanating from these begins the 5’-3’ strand-elongation through 
thermoresistant polymerases upon usage of dNTPs and magnesium. 
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For analytical purposes the Taq polymerase (from thermophilus aquaticus) was used. It 
amplifies 1000 nucleotides per minute and creates an adenosine- 3’-overhang. Moreover it 
does not possess a proof reading ability.  
However to amplify with a high accuracy, for preparative purposes, Pfu-polymerase was 
used. It possesses a proof reading ability and amplifies 500 nucleotides per minute.  
 
Pipetting instruction: 
100ng Template 
1µl Primer forward (10µM) 
1µl Primer reverse (10µM) 
5µl Polymerase buffer (10x) 
1µl dNTPs (10mM) 
0,5µl Polymerase (Pfu Polymerase or DreamTaq, both Fermentas) 
ad 50µl H2O 
 
The thermocycler-protocol was adapted each time to the individual PCR-reaction, adjusting 
the annealing-temperature, elongation time and cycle number. 
1 Cycle initial denaturation 2 min 95°C 
denaturation 30 s 95°C 
primer annealing 30 s 
temperature primer-
dependent 
25-35 
Cycles 
elongation 
1 min per 1000 bp (Taq) 
2 min per 1000 bp (Pfu) 
72°C 
1 Cycle final elongation 10 min 72°C  
1 Cycle cooling ∞ 4°C 
 
METHODS 
 53 
6.2.3.2 Colony – PCR 
Colony-PCR is a fast and easy method to check if a plasmid with insert is present in selected 
transformed bacteria-clones. The principle is equal to a standard PCR, except that bacteria 
clones are directly used as template, instead of purified DNA. Clones are picked with a sterile 
tip from a plate and the tip is first swiveled in sterile dH2O and then put into 3ml of LB-Amp 
Medium to be able to grow positive clones subsequent to testing for inserts. The H2O-bacteria 
suspension is then used in a PCR reaction with primers specific for the inserted DNA-
sequence. 
6.2.3.3 Reverse transcription PCR (RT-PCR) 
Reverse transcription PCR is used to transcribe mRNA into cDNA using the enzyme reverse 
transcriptase. 
RT-PCR was conducted using the RETROscript Kit (Ambion) according to manufacturers 
instructions. 
6.2.3.4 Sequencing of DNA 
Sequencing of DNA, based on a chain termination-reaction190 was conducted by the company 
eurofins mwg operon. 
6.2.4 Purification of plasmid DNA  
The methods of purification of plasmid DNA out of bacteria clones are based on the principle 
of alkaline lysis. Proteins, chromosomal and plasmid DNA are thereby precipitated. Spinning 
down clears the solution of proteins and chromosomal DNA, whereas RNA is degraded by 
the use of RNases.  
For Maxi-preparations the QIAfilter Plasmid Maxi Kit was applied. It is also based on 
alkaline lysis, the spinning step however is replaced by application of an anion-exchange-
resin. DNA binds to that resin at low salt and low pH condition and can after washing with a 
medium salt buffer be eluated by a high salt solution. 
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6.2.5 DNA extraction from tissue samples 
To obtain DNA from tissue samples like ear or tail pieces they were first digested with an 
appropriate amount of digestion buffer (ALT buffer, Blood and Tisssue Kit, Qiagen; 90µl for 
ear samples) and proteinase K (10µl for ear samples). Digestion was carried out at 56°C for 
about 5 hours, with regular vortexing inbetween. Following the DNA was precipitated. 
6.2.6 Gel extraction of DNA 
To extract DNA out of an agarose gel, the QIAquick Gel Extraction Kit was used, according 
to manufacturers instructions. 
6.2.7 Purification of digested vectors and PCR-products 
To clear DNA from buffers used in restriction digest or PCR QIAquick PCR Purification Kit 
was used, according to manufacturers instructions. 
6.2.8 Photometric concentration-measurement of DNA 
DNA concentration was measured per photometer by absorption at a wavelength of 260 nm. 
This is the maximal absorption for nucleic acids. The purity of DNA can be detected by 
taking the ratios of OD260/280 and OD260/230. Absorption at 280 nm shows contamination 
through proteins, at 230 nm through peptides, aromatic compounds and carbohydrates. The 
ratios for pure nucleic acids should be: OD260/280 = 1,8 and OD260/230 = 2,0. 
6.2.9 Restriction digest of DNA 
Restriction endonucleases of type II cut DNA specifically at a defined, mostly palindromic 
sequence motive of 4-6 nucleotides length. The double strand cleavage is hydrolytic and gives 
rise to either a blunt, 5’ or 3’ sticky end.  
Pipetting instruction: 
2µg DNA 
2µl Buffer (10x) 
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0,3µl Restriction enzyme 
(optional 0,3µl second restriction enzyme) 
ad 20µl H2O 
The mixture was incubated at 37°C for 2-3h. 
6.2.10 Dephosphorylation 
In order to avoid religation of a digested vector, the generated 5’ ends were dephosphorylated 
by calf intestine phosphatase (CIAP).  
1µl of CIAP was added 1h before the end of the restriction digest. After the incubation 
period, the enzyme was inactivated at 85°C for 10 minutes. 
6.2.11  Ligation of DNA fragments 
Ligation connects DNA-fragments with complementary DNA-overhangs. The enzyme 
working in this process is the T4-Ligase. It creates a new phosphodiester bond in the DNA-
backbone under usage of one ATP molecule. For a successful ligation, vector and insert have 
to be available in stoichiometric amounts. A 1:4 ratio has proved to be suitable.  
Pipetting instruction: 
100ng Vector 
4 x Insert 
1µl T4 Ligase (Fermentas) 
1µl T4 Ligase buffer 
ad 10µl H2O 
The incubation was carried out for 4 hours at room temperature.  
6.2.12 RNA isolation from organs 
Mice were sacrificied by isofluran inhalation. After disinfection of the fur the internal cavity 
was exposed and organs of interest taken out. They were directly put into 1ml of Trizol, 
immediately homogenized and processed according to manufacturer’s instructions.  
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6.2.13 DNAse I treatment of RNA 
In order to prevent false positive signals in the quantitative PCR a DNase I digest was 
performed. For this the DNase I from Fermentas was used according to manufacturer’s 
instructions. 
6.2.14 cDNA production 
The DNase I digested RNA was used to produce cDNA via the Roche Transcriptor First 
Strand cDNA Synthesis Kit. OligodT Primer as well as Random Hexamers bind to RNA and 
form the starting point for the Reverse Transcriptase to synthesize cDNA. 
 
6.2.15 Quantitative real time PCR 
Measuring the amount of mRNA in cells or tissues is possible via quantitative real time PCR. 
In addition to the conventional PCR method, it includes the binding of fluorescent probes to 
the template cDNA. The probes used in this report were obtained from the Universal Probe 
Library (UPL) from Roche. These are labeled at the 5’ end with a FAM reporter and are 
quenched by a dark quencher at the 3’ end. As the probe anneals together with the primers to 
the cDNA template, it is degraded by the 5’-3’ exonuclease activity of the Taq polymerase. 
By this, the FAM reporter is set free and gives a fluorescent signal that is detectable via Laser 
excitation and increases together with the product during the PCR. To enable a relative 
quantification, a reference gene, here GAPDH, was measured along with the gene of interest.  
 
Procedure: 
 Pipetting instruction: 
5µl  2x Fast Start Universal Probe Master (Rox) (Roche) 
0,4µl  Primer fwd (10µM) 
0,4µl  Primer rev (10µM) 
2,1µl  H2O 
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0,1µl UPL Probe (10µM) 
2µl cDNA (diluted 1:2) 
 
The reaction was conducted in a 384 well plate that was closed with adhesive seals and 
shortly spun down prior to the reaction. Usually Triplets were measured. 
PCR protocol: 
1 Cycle 
initial denaturation 
and hot start of Taq 
Polymerase 
10 min 95°C 
denaturation 15 s 95°C 
40 
Cycles 
primer /probe annealing 
and elongation 
1 min 60°C 
 
In the result analysis the threshold cycles (Ct), the cycles in which the fluorescent signal of a 
sample rises above the background signal, of reference samples and target samples were put 
in relation to obtain a relative quantification. 
ΔCt = Ct target  - Ct reference 
6.3 Protein biochemistry 
6.3.1 Preparation of protein lysates from cells 
Suspension cells could be spun down and resuspended in RIPA buffer, supplemented with 
Protease Inhibitor Cocktail (x10; Sigma) and DNase I (x1000; Invitrogen). For up to 5 million 
cells 60µl of this homogenization buffer was added. All samples were kept on ice for 15 
minutes and vortexed intermittently. Subsequently the samples were spun down again and the 
supernatants transferred to a new tube. The lysates were stored at -80°C. 
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6.3.2 Preparation of protein lysates from tissues 
Tissues, e.g spleen, were homogenized on ice with a rotor-stator homogenizer in 500µl RIPA 
buffer, supplemented with Protease Inhibitor Cocktail. Following procedures were conducted 
as described in the previous section. 
6.3.3 Quantification with bicinchoninic acid (BCA) assay 
A small protein lysate aliquot was reserved for protein quantification by using the BCA assay, 
since the RIPA buffer does not interfere with it. The Novagen® BCA Protein Assay Kit 
(Merck) was used according to manufacturer’s instructions.  
6.3.4 Protein Gel Electrophoresis 
Proteins can be separated by size via gel electrophoresis. In this report the NuPAGE® Bis/Tris 
Precast Gel System (Invitrogen) was used, which is based on the traditional SDS-PAGE 
system according to Laemmli191. However the lower pH of the NuPAGE® system ensures 
higher protein stability, which was crucial for the detection of CLEC16A. To further provide 
stability, all samples were defrosted and kept on ice only shortly before starting the 
procedure. Reducing agent (10x) and NuPAGE®  4x LDS Buffer (both Invitrogen) were 
added prior to denaturing the samples at 70°C for  five minutes. Following the samples were 
cooled down for five minutes on ice and then spun down. The supernatants were loaded onto 
a NuPAGE® 10 well 1.0mm 4-12% Bis Tris gel that was set up with MOPS buffer and 
antioxidant (both Invitrogen) in the running unit. The separation was then conducted at 200V 
for about one hour. 
6.3.5 Western Blot 
Transfer of proteins from an acrylamide gel to a membrane, here nitrocellulose, is possible by 
using the method of western blotting. Here the proteins migrate again along an electrical field 
towards the anode. The migration takes place in a tank blot chamber, which is filled with 
transfer buffer. In order to ensure an even transfer, all components of the assembly had to be 
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pre soaked in transfer buffer and be built up without air bubbles. The transfer was carried out 
at 100V for one hour in the cold room.  
 
6.3.6 Detection of proteins on  membranes 
Detection of specific proteins on nitrocellulose membranes is possible by staining with 
specific antibodies. To prevent unspecific binding the membrane first had to be blocked in 
5% milk powder in TBS-T 0,05% (blocking buffer) over night at 4°C.  
The membrane could then be incubated for one hour at room temperature with the primary 
antibody, which had been diluted in 6ml blocking buffer. Subsequently the membrane was 
rinsed in dH2O and washed three times for ten minutes with TBS-T 0,2% (wash buffer). After 
that the incubation with the matching horse radish peroxidase (HRP)-coupled secondary 
antibody was carried out again in 6ml blocking buffer for one hour at room temperature. 
Excess Antibody was washed from the membrane again by rinsing with dH2O and washing 
three times with wash buffer.  
To detect the signal of the HRP, the membrane was dried with tissue and then incubated for 
one minute with enhanced chemiluminescence reagent. It contains luminol that is catalyzed 
by the peroxidase under emission of light. For luminescence detection the… was used. 
6.3.7 Luciferase Assay 
The in vitro validation of the knockdown efficiency of a specific shRNA was tested by 
performing a luciferase assay. 293F cells were plated out on a 24-well plate at a density of 2,5 
x 105. The next day they were cotransfected with 300ng of the shRNA construct as well as 
with 100ng of the reporter plasmid psiCHECK2 carrying the target cDNA.  
The psiCHECK2 vector contains sequences for two luciferases, Renilla and Firefly. The 
Firefly sequence is expressed constitutively and serves for normalization purposes. The 
Renilla luciferase is however expressed together with the target cDNA in a bicistronic mRNA 
and gets degraded alongside the target sequence if the an appropriate shRNA is added.  
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After two days incubation the cells were washed once with PBS and are then lysed with 
passive lysis buffer (Promega). The luciferase activity was measured in an opaque 96 well 
plate, using 5µl of the cell suspension and the Dual-Luciferase® system (Promega). The 
measurement was carried out in a Fluostar Optima luminometer. 
6.3.8 Enzyme-linked immunosorbent assay (ELISA) 
ELISAs were performed for measuring IFNγ and IL-2 levels. Matching Ready-Set-Go!® Kits 
from eBioscience were used according to manufacturers instruction. 
6.3.9 Cytometric Bead Array (CBA) 
Multiple cytokines could be measured simultaneously by using the Cytometric Bead Array® 
System from BD. IL1, IL-2, IL-4, IL-6, IL10, IL-12, IL17A, TNF and IFNγ were detected by 
using this method.  Briefly, antibodies, bound to uniquely labeled beads, bind to soluble 
proteins and thus make it possible to detect them via flow cytometry. A second antibody, 
labeled with another fluorophore binds to the bead-bound protein and shows the abundance of 
it via its mean fluorescent intensity. The Kit was used according to manufactures instructions, 
however amounts of buffers and samples were reduced to one fifth of the suggested volumes. 
Results were analyzed with the FCAP Array® software (BD). 
6.4 Cell biological methods 
All eukaryotic cell lines as well as primary cells mentioned in this report were cultured in the 
appropriate media at 37°C and 5% CO2. Spinning, if not explicitly described otherwise, was 
always carried out at 453g for 7 minutes at 4°C. All media were preheated to 37°C before use 
and were sterile. 
6.4.1 293F Cell line 
The 293F cell line is derived from human embryonic kidney cells and is a fast growing 
variant of the standard 293 cell line. It was maintained on advanced DMEM supplemented 
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with 10% FCS, penicillin / streptomycin and glutamine. Cells were passaged every 3 days in 
a 1:10 ratio. Ideally the cell density did not exceed 80%.  
6.4.2 Evaluation of cell density 
Cell density was quantified via a Neubauer hemocytometer. The cells were resuspended and 
mixed (mostly in a 1:10 ratio) with trypan blue. The staining allows to distinguish between 
living and dead cells, since the dye only enters dead cells. Per definition one quadrant of the 
hemocytometer has a volume of 0,1 µl. 
From the number of cells in one quadrant the cell concentration in the cell suspension can be 
calculated. To minimize the statistical error, four quadrants were counted. 
 
D = N/Q x V x 104 
with: D  = cell concentration per ml 
N  =  number of counted cells 
Q  =  number of counted quadrants 
V  =  dilution factor of cells (mostly 10) 
6.4.3 Transfection of eukaryotic cells  
Introduction of foreign DNA, in this case plasmid DNA, into eukaryotic cells is called 
transfection. The transfection agent used here was Fugene 6 (Roche), a cationic lipid. After 
mixing this reagent with plasmids, it coats and condenses them by electrostatic association. 
The overall positively charged complexes associate with negatively charged cell surfaces and 
are internalized via endocytosis. Eventually the lipids provided in the transfection agent work 
in destabilizing the endosomal membrane by inducing non-bilayer lipid structures. By this 
cytoplasmatic delivery of the introduced plasmids is facilitated 192.  
Protocol: 
On day 0 confluent 293F cells were split in a 1: 2,5 ratio onto a new cell culture plate. They 
reached 80% confluence on the next day on which they could be transfected with the 
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plasmids of interest. These were premixed with serum free medium and Fugene 6. After 30 
minutes of incubation at room temperature the mixture was added drop wise to the cells. 
Depending on the size of the culture plate, different amounts of DNA and transfection reagent 
were used: 
• 20 cm plate: 35 µg DNA with 70 µl Fugene 6 in 1ml serum free medium 
• 10 cm plate: 10 µg DNA with 30 µl Fugene 6 in 500 µl serum free medium 
• 6 well plate: 2µg DNA with 8 µl Fugene 6 in 150 µl serum free medium 
6.4.4 Virus production 
6.4.4.1 shRNA-pLBM construct 
Design of the shRNAs was done by using the algorithm which is available online at 
http://katahdin.cshl.org:9331/homepage/siRNA/RNAi.cgi?type=shRNA. Synthetic oligos 
were ordered from Sigma-Aldrich. To generate a double strand, sequences were amplified per 
PCR and then cloned into the pLBM vector between the XhoI and EcoRI recognition sites. 
 
 
Figure 4: Map of pLBM vector 
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6.4.4.2 Production of lentivirus 
Lentiviruses were used to introduce genes or shRNAs into the genome of cells. To produce 
them, 293F cells were cotransfected with the lentiviral vector, carrying the DNA sequence of 
interest flanked by LTRs (pLBM) and helper vectors. For production of larger amounts of 
virus, 20 cm plates were transfected with  
• 3 µg pCMV VSVg 
• 3 µg RSV-rev 
• 4 µg pMDL-gag/pol rre 
• 5 µg pAdvantage 
• 20 µg pLBM 
The cell supernatant containing the produced virus was collected 48 h and 72 h after 
transfection. To remove 293 cells and cell debris the supernatants were first spun down for 7 
minutes at 1065g and then filtered through a 0,45µm filter. Following the supernatants were 
ultra centrifuged for 90 minutes at 25000 rpm (ultracentrifuge, Beckmann), thereby 
concentrating the virus into the pellet. After aspirating the supernatant thoroughly and 
carefully, the pellet was resuspended in 100 µl sterile PBS by overnight incubation at 4°C. If 
not used immediately, the viral suspension was split into 25µl aliquots, frozen in liquid 
nitrogen and stored at -80 °C.  
6.4.5 Lentivirus titration 
To assess the concentration of virus particles in the concentrated virus suspension 293 F cells 
were infected. On day 0 they were plated out at a density of 4 x 105 cells / well in a 6 well 
plate. On the next day the cell supernatants were removed and reconstituted by a virus 
dilution of 1 µl virus in 1 ml fresh medium. To be able to calculate also very high virus 
concentrations, the cells were also infected with a 1:10 and 1:100 dilution of the initial virus 
suspension. On day 3 or 4 the percentage of infected cells could be assessed from GFP 
expression, which was quantified from FACS analysis. 
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6.4.6 Flow cytometry 
Cell suspensions can be analyzed very specifically by means of flow cytometry. The method 
allows an examination of cell number, size, granularity and presence of specific antigens. 
These have to be stained by fluorescently labeled antibodies. Also the expression of 
fluorescent proteins like GFP can be analyzed.  
Inside the flow cytometer a cell suspension is aspirated in a capillary in which the cells 
individually pass a laser beam. This causes the light to be scattered and in case of 
fluorescence a shift in the maximal emission to higher wavelengths. There are several 
detectors picking up the scattering, one in line with the laser (forward scatter, FSC) and some 
perpendicular to it (side scatter, SSC and fluorescence detectors). The FSC picks up the 
diffraction, which gives information about the particle size. The SSC however is determined 
by the scattering of light, defining the granularity of cells.  
All measurements were done at the BD FACSCantoII™ or on the BD FACSAriaIII™. 
Analyzes were carried out using the FlowJo 9.2© (Tree Star) software. 
6.4.6.1 Extracellular staining of cells for flow cytometry 
Staining was always performed on cells in suspension. 100 µl of a cell suspension containing 
about 3-5 x 105 cells in PBS supplemented with 1% FCS (PBS 1% FCS) were if necessary 
first blocked with Fc-receptor block for 10 minutes at 4°C. After that the directly labeled or 
biotinylated antibodies could be added. The antibody dilution was titrated previously 
individually for every antibody. After 20 minutes incubation at 4°C in the dark, the cells were 
washed once with PBS 1% FCS. If needed, secondary antibodies or fluorescent labeled 
streptavidin was added to the cells and incubated another 30 minutes at 4°C. After the final 
washing step, the cells could be resuspended in 300-400 µl PBS 1 % FCS before FACS 
analysis. 
METHODS 
 65 
6.4.6.2 Intranuclear staining of Foxp3 
Staining of the transcription factor Foxp3 in primary murine T cells was performed using the 
Foxp3 staining Kit of eBioscience according to manufacturer’s instructions. 
6.4.6.3 Intracellular staining of CTLA-4 
Intracellular staining was carried out on 1 x 106 cells per tube. The Fc-receptors were first 
blocked with Fc-Block for 10 minutes at 4°C. After that the surface staining was performed as 
described above. To fix the cells they were subsequently treated with 2% paraformaldehyde 
(PFA) for 10 minutes at room temperature in the dark. For a gentle permeabilisation the cells 
were first washed with 0,03% saponin in PBS. The staining with anti-CTLA-4 however was 
then conducted in 0,3% saponin, supplemented with 2% FCS. Per 1 x 106 cells 1µg of 
antibody was required. To ensure an even permeabilisation and staining the suspension was 
vortexed before incubation at 4°C in the dark for 30 minutes. Before FACS analysis the cells 
were washed twice with 0,03% saponin and once with pure PBS. 
6.4.6.4 Fluorescence-activated cell sorting 
Sorting of cells was conducted at the BD FACSAriaIII™ using BD FACSDiva™ Software. 
The nozzle size was chosen according to the type of cells being sorted. Lymphocytes were 
sorted with the 70µm nozzle, Macrophages by using the 85µm nozzle. Before starting to sort, 
the stream had to be adjusted for drop delay and spillover.  Samples were acquired with a 
proper compensation and without a threshold value. Gates were set stringently to avoid 
contamination in the sorted subsets. In general, sorting precision was set to “purity”.  
 
6.5 Histology 
6.5.1 Sample preparation for colon histology 
For histology, mice were sacrificed by isofluran inhalation, the fur was disinfected and the 
internal cavity was opened. The colon was taken out in one piece from the rectum to the 
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caecum, mesenteric connections being removed in the process. Subsequently the colon was 
placed immediately in 4% PFA fixative and incubated at 4°C over night to ensure a thorough 
fixation. 
The fixed colon could then be further processed by excising four approximately 4mm long 
tubes from different sections. Then the tubes were very carefully cleaned from feces without 
injuring the tissue. 
6.5.2 Paraffin processing and embedding of tissues  
Fixed and prepared colon tubes were placed in embedding cassettes and put in the processing 
machine over night. Here an increasing Ethanol series was operated before exchanging the 
medium for Xylene and then paraffin wax. 
On the next day the tissues could be embedded in paraffin wax. 
6.5.3 Paraffin sections 
Paraffin blocks were trimmed and cut at the microtome into 3-4µm sections. Sections were 
then stretched on a large drop of dH2O placed on a SuperFrost® plus glass slide (Menzel-
Gläser), by putting the slides on a 37°C heating plate. After the section had stretched 
completely, the water was removed by applying pressure with an ethanol soaked filter paper.  
6.5.4 Deparaffinization of tissue sections 
Dried tissue sections were deparrafinized by incubating the slides twice for five minutes in 
Xylene. Following the slides were put through a descending ethanol series from 100% to 
70%, incubating two minutes in each concentration. Finally the slides were put into dH2O for 
2 minutes. 
6.5.5 Hematoxylin / Eosin staining (H/E staining) 
The rehydrated tissue slides were immediately incubated in Hämalaun Mayer for 3 ½ minutes 
and then put under running tap water for ten minutes to ensure bluing of the Hematoxylin. 
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The slides were then dipped in dH2O and stained in Eosin for 45 seconds. Careful not to wash 
away the water soluble  Eosin, the slides were only dipped very shortly in dH2O to remove 
excess dye and then put into an ascending ethanol series starting right away with 96% 
ethanol. Finally the slides were incubated twice in Xylene for five minutes and then mounted 
in the xylene-based medium Eukitt. 
6.5.6 Colitis scoring 
Scoring of colon sections for colitis was performed in a blind fashion by Dr. Alma Zernecke. 
The sections were scored into four stages 0-4193: grade 0 = no changes; grade 1 = minimal 
scattered mucosal inflammatory cell infiltrates, with or without minimal epithelial 
hyperplasia; grade 2 = mild scattered to diffuse inflammatory cell infiltrates, sometimes 
extending into the submucosa and associated with erosions, with minimal to mild epithelial 
hyperplasia and minimal to mild mucin depletion from goblet cells; grade 3 = mild to 
moderate inflammatory cell infiltrates that are sometimes transmural, often associated with 
ulceration, with moderate epithelial hyperplasia and mucin depletion; grade 4 = marked 
inflammatory cell infiltrates that are often transmural and associated with ulceration, with 
marked epithelial hyperplasia and mucin depletion194. 
6.6 Mice 
6.6.1 Generation of transgenic mice 
Depending on the project, B6 or NOD (non obese diabetic) single cell embryos (B6 and NOD 
for KIAA0350 knockdown and NOD for sCTLA-4 knockdown) were injected with the 
relevant virus sample containing a shRNA-bearing vector (pLBM). Living embryos were then 
transferred into pseudopregnant foster mice (CD1). The procedure was carried out by Nicole 
Hain. Successful incorporation of the shRNA could be verified by taking blood of the 
offspring, because of the presence of a GFP reporter in all constructs. GFP positive mice were 
further bred to obtain homozygous mice. 
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6.6.2 Diabetes monitoring 
NOD mice are genetically prone to develop diabetes at 12-16 weeks of age. The onset of 
diabetes was determined by weekly testing of glucosuria with Diastix® (Bayer). A mouse was 
considered diabetic at the first of two consecutive positive results. 
6.6.3 Adoptive transfer of lymphocytes into NOD.SCID mice 
NOD.SCID mice are homozygous for a autosomal recessive mutation in the Prkdc gene. It 
results in a severe combined immunodeficiency, caused by a lack of functional T- and B-
lymphocytes. Natural killer cells and the circulating complement system are also affected.   
Lymphocytes for adoptive transfer were washed and resuspended in sterile PBS. 200µl of the 
cell suspension were injected into the tail vein. 
6.6.4 Cyclophosphamide mediated diabetes induction 
Upon administration of low dose cyclophosphamide (CY), an alkylating chemotherapeutic 
drug, NOD mice simultaneously develop diabetes195-197. The onset occurs around two to three 
weeks after administration and correlates with the loss of natural regulatory T cells195,197,198. 
NOD mice were injected on day 0 and day 14 with 200mg/kg cyclophosphamide. Adoptively 
transferred NOD.SCID mice were injected only once on day 21 after transfer. 
 
Figure 5: Impact of low dose CY treatment on lymphocyte numbers, modified from 
Brode and Cooke, 2008198 
METHODS 
 69 
 
6.6.5 Colitis induction 
NOD.SCID mice develop colitis upon adoptive transfer of CD4+CD45RBhi lymphocytes199. 
We transferred 4 x 105 WT CD4+CD45RBhi cells  alone or with 105 CD4+CD25+ Tregs from 
WT NOD or sCTLA-4 KD NOD mice into NOD.SCID recipients. After 8-9 weeks, mice 
were sacrificed and histology of the colon was performed.  
6.7 Immunological Assays 
6.7.1 Cell-sorting using magnetic beads 
Mice were euthanized by isofluran inhalation. Then, the fur was disinfected and the internal 
cavity exposed. Lymph nodes and spleen were dissected and ground between two rough 
microscope slides in 5 ml of PBS 1% FCS. For dendritic cells the spleen had to be incubated 
in Collagenase (Liberase Blendzyme, Roche) for 20 minutes before grinding. Erythrocytes 
were lysed, remaining cells washed and filtered with a 40µm filter, ensuring a single-cell 
suspension. This was subsequently used in different magnetic cell sorting kits (MACS, 
Miltenyi or Dynabeads®, Invitrogen). 
6.7.2 Proliferation assays 
All proliferation assays were carried out in RPMI-10 (RPMI1640, supplemented with 10% 
FCS, antibiotics, glutamine, 2-Mercaptoethanol and sodium pyruvate) medium in a 96-well 
(U-bottom) plate.  
Magnetically sorted CD4 T cells or lymphocytes were activated with different concentrations 
of anti-CD3, PMA/Ionomycin or beads coupled with anti-CD3 and anti-CD28. 
B cells were activated with different concentrations of Lipopolysaccharide (LPS) or anti-
CD40. 
METHODS 
 70 
To assess the proliferation, 0,5µCi thymidine3H (in RPMI-10) were added per well after 72h 
incubation at 37°C and 5% CO2. 16h hours later the plate was harvested and incorporated 
radioactivity analyzed with help of a beta-counter (Perkin-Elmer).  
Alernatively the cells were stained initially with Cell Proliferation Dye eFluor® 670 
(eBioscience) according to manufacturers instructions. Proliferation could then be measured 
via flow cytometry and dilution of the dye. 
6.7.3 Suppression assay 
To carry out a suppression assay to assess the suppressive activity of regulatory T cells in 
vitro, effector T cells (CD4+CD25-) and Treg cells (CD4+CD25+) from young (6-8 weeks) 
male NOD mice were purified using MACS. After cell purification, 25.000 effector T cells 
were mixed in different ratios with Treg cells (1:1 up to 1:32) in RPMI-10 supplemented with 
1µg/ml anti-CD3 in a 96-Well (U-bottom) plate. Costimulation was provided by 400.000 
APCs (irradiated spleen cells) per well. After 72h incubation, proliferation was assessed by 
incorporation of radioactively labeled thymidine.  
6.7.4 Coculture of dendritic cells with Treg cells 
Effector T cells (Teff, CD4+CD25-), Treg cells (CD4+CD25+) as well as dendritic cells 
(CD11c+) were purified using MACS. Teff asl well as Treg cells were then stained with 
0,5µM CFSE. In RPMI-10 with 1µg/ml anti-CD3, cells (usually 40.000 DCs and 150.000 
Tregs or Teffs or both) were mixed together in a 96-well U-bottom plate and incubated for 
42h at 37°C and 5%CO2. Before staining for flow cytometric analysis, cells and wells were 
treated with 3mM EDTA 1% FCS in PBS to prevent the dendritic cells from sticking to the 
wells and to separate dendritic cells from T cells, since they are claimed to form clusters118. 
6.7.5 Staining of phosphorylated ZAP70 
Before staining of phosphorylated ZAP70 the T cells had to be activated. First a single cell 
suspension was created from lymph nodes. 1 x 106 cells were added to a FACS tube in 50µl 
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RPMI10 and then activated with 10µg/ml anti-CD3 (hamster anti mouse, in 50µl RPMI10). 
After 30 minutes incubation on ice, cells were washed with RPMI10. Next the anti-CD3 
antibody was cross-linked by incubation with 10µg/ml anti-hamster (100µl in RPMI) for 15 
minutes on ice. T cells were  then activated in a water bath at 37°C for different periods of 
time. Immediately after activation the cells were fixed with 2% PFA for 5 minutes at room 
temperature. After a washing step cells were permeabilized by adding 0,5ml 2%PFA and 4ml 
Methanol and incubating 30 minutes on ice in the dark. Washing was now performed with 
PBS 0,5% BSA, which was then also used to block the cells for 15 minutes before adding the 
antibody. The antibody for ZAP-70 (20µl/ 1 x 106 cells) was then incubated for one hour at 
room temperature in the dark. Flow cytometric analysis could be carried out after a washing 
step with PBS 0,5% BSA. 
6.7.6 In vitro differentiation of regulatory T cells 
In order to produce induced Treg cells, naïve T cells (CD4+CD62L+) were isolated from 
murine lymph nodes cell suspensions via magnetic cell separation. The naïve T cells were 
then incubated in a 24-well plate at a concentration of 0,5 x 106 cells/ml with 2µg plate bound 
anti-CD3, 2µg soluble anti-CD28 and 2ng TGFβ  in RPMI10 for 4 days at 37°C and 5% CO2. 
6.7.7 Mixed lymphocyte reaction 
T cells are MHC restricted, however about 1-10% of them respond to allogeneic MHC 
molecules and recognize them as foreign. To test this ability to proliferate upon stimulation 
with foreign MHC, 2 x 105 splenocytes from NOD or NOD CLEC16A KD mice were mixed 
together with 2 x 105 irradiated (20 Gy) NOD, NOD CLEC16A KD or C57BL/6 splenocytes. 
The cells were cultured together in RPMI10 for 72h, before 0,5 µCi thymidine3H was added 
for the last 16h of culture. The proliferation could then be measured by harvesting the 
incorporated radioactive thymidine. 
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6.7.8 Enrichment of thymic epithelial cells (TECs) 
The protocol for the thymic epithelial cell (TEC) isolation was kindly provided by Prof. Dr. 
Ludger Klein (LMU, Munich).  
Thymi were put in a 60 mm culture dish on ice and connective tissues were removed carefully 
with forceps, before the thymi were minced with scissors. 500 µl of RPMI with 0,2 mg/ml 
collagenase and dispase I (both Roche) as well as DNase (Invitrogen) were then added and 
pipetted up and down with a cut-tip P1000. The suspension was then incubated for 30 minutes 
at 37°C, during witch it was frequently pipetted up and down with a Pasteur pipet, that had 
been heated briefly in a burner flame, to minimize the opening size. Once a single cell 
suspension had been produced, EDTA (0,36 M) was added to a final concentration of 10 mM 
and incubated for another five minutes to break up rosettes. The suspension was then filtered 
through a 40 µm Falcon filtered and washed with PBS 1%FCS. After that a Percoll gradient 
was layered in a 15 ml Falcon tube. For that, the tube was first coated with 2 ml and then 
drained upside down. Then the spinned cells were resuspended in 4 ml Percoll (density 1.115) 
and transferred into the 15 ml tube. Above the cell layer, a less dense Percoll layer (density 
1.06) of 2 ml was carefully and slowly pipetted with a Pasteuer pipet, while tilting the tube 
45°. On top a 1ml layer of PBS was carefully stacked. The gradient was then centrifuged at 
1350g for 30 minutes at 4°C without a brake. The layer between the less dense Percoll and 
PBS then contains the TECs, they were carefully aspirated with a Pasteur pipet. Between the 
dense and the less dense Percoll layer the thymocytes are positioned. The cells are then 
washed once more with PBS 1%FCS. 
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7 Results 
7.1 Functional study of sCTLA-4 in T1D 
The CTLA4 susceptibility polymorphism CT60 correlates with a reduction of the sCTLA-4 
splice variant expression. To elucidate if this reduction is causal for conveying susceptibility 
and shedding light on the mechanism behind it is the objective of this thesis.  
For this purpose transgenic NOD mice bearing a knockdown for sCTLA-4 were generated by 
Stephan Kissler. To introduce this project and facilitate comprehension, the generation and 
first phenotyping of the transgenic mice will be described although they were not part of this 
thesis. 
7.1.1 ShRNA design and in vitro validation 
Mice in contrast to humans have 3 different splice isoforms of CTLA-4. In addition to full 
length CTLA-4 and sCTLA-4 there is a transcript called ligand independent CTLA-4, lacking 
the second exon. Since the splice isoform sCTLA-4 should be targeted specifically without 
influencing other splice products, the shRNA was designed to bind the junction between exon 
2 and 4, which is unique for sCTLA-4 (Figure 6).  
 
 
Figure 6:  Design of splice isoform specific shRNAs 
 
The shRNA was cloned into a pLBM vector behind the reporter gene GFP, so that a 
bicistronic mRNA is transcribed. Both sequences are under control of a CMV promoter and 
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lie between two long terminal repeats (LTRs, Figure 7) which contain the signals of 
integration for the viral integrase. 
 
Figure 7:  Integration cassette of the pLBM vector, bicistronic RNA transcript and 
RNAi pathway 
 
Subsequently for validation of the knockdown efficiency and specificity of the shRNA 
directed against sCTLA-4, the cDNAs of the different murine CTLA-4 isoforms were cloned 
into the psiCHECK-2 vector and a luciferase assay was performed. This in vitro reporter 
assay is based on the bicistronic expression of the target-cDNA and renilla luciferase. Both 
vectors, the pLBM-sCTLA-4-shRNA and one of the three psiCHECK (full length (fl), soluble 
or ligand independent (li)-CTLA-4) were then transfected into 293F cells and the knockdown 
was measured for all three sequences (Figure 8). 
 
Figure 8:  Luciferase assay validating specific and efficient knockdown through 
sCTLA-4-shRNA, data provided by Stephan Kissler 
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The knockdown was thus demonstrated to be efficient (around 90%) and specific for  
sCTLA-4 alone. 
7.1.2 Generation of transgenic mice and in vivo knockdown validation 
Since the shRNA proved to be reactive and specific in vitro the construct was used to produce 
lentivirus. This was then injected into NOD embryos and resulting transgenic pups were bred 
to be homozygous to reduce variegation. Integration of the shRNA-EGFP construct was 
assessed on DNA level by southern blot with a probe against EGFP (Figure 9 A) and also on 
protein level by flow cytometric analysis of splenocytes (Figure 9 B).  
 (A)  (B) 
Figure 9:  (A) Southern Blot for EGFP with DNA from wildtype NOD and B6 and 
transgenic NOD containing the shRNA(sCTLA-4)-GFP construct (data: 
Florian Beck); (B) FACS for GFP expression in wildtype (WT) and sCTLA-
4 knockdown cells (data: Stephan Kissler) 
 
Both demonstrate the expression of GFP in the transgenic animals. The FACS data 
additionally quantifies the GFP expressing splenocytes to about 60-70% of the total cell 
number. 
Still the insertion and expression of the reporter does not give proof that the shRNA is 
functional also in vivo. Since there is no antibody for sCTLA-4 available, the knockdown 
verification was accomplished by quantitative real time PCR on splenocytes. Along with the 
expression of sCTLA-4 in WT and transgenic animals, the mRNA level of flCTLA-4 and 
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liCTLA-4 was defined, showing that the mRNA level for sCTLA-4 alone is specifically 
reduced in transgenic animals (Figure 10 A). The degree of reduction can be calculated from 
the difference in cycles and amounts to about 70% (Figure 10 B). 
 
(A) (B) 
Figure 10: (A) Quantitative real time PCR for flCTLA-4, sCTLA-4 and liCTLA-4 in 
WT and transgenic NOD splenocytes; (B) differences of cycles (data: Dan 
Rainbow, Cambridge) 
7.1.3 Characterization of cell ratios 
The quantitative real time PCR had revealed that there indeed is a specific sCTLA-4 
knockdown in the transgenic mice. With that knowledge phenotyping of the sCTLA-4 
knockdown (sCTLA-4 KD) could be started.  
Given that CTLA-4 is expressed by T cells, and CTLA-4 -/- mice show a skewing of the 
CD4/CD8 cell ratio towards the CD4 lineage200, ratios of different T cell subsets were 
analyzed first. Developing T cells in the thymus can be characterized in their stage of 
development for instance by expression of the both surface markers CD4 and CD8. When 
staining thymi of WT and sCTLA-4 KD mice for those two markers no differences in DN, 
DP or single positive cell ratios were observed (Figure 11). 
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Figure 11: FACS staining of WT and sCTLA-4 KD thymi for CD4 and CD8 (data: 
Stephan Kissler) 
 
Also in the spleen, where mature T cells are present, CD4+ vs CD8+ T cell percentages were 
the same in WT and sCTLA-4 KD mice (Figure 12). 
 
 
Figure 12: FACS staining of WT and sCTLA-4 KD spleens for CD4 and CD8 (data: 
Stephan Kissler 
 
CTLA-4 is an activation marker for conventional T cells. As a consequence looking for other 
activation markers seemed reasonable. Thus spleen cells were stained for CD5 and CD25, 
showing a similar activation status in WT and sCTLA-4 KD spleens (Figure 13). 
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Figure 13: FACS staining of WT and sCTLA-4 KD spleens for CD5 and CD25 (data: 
Stephan Kissler) 
 
Subsequently CD4/CD8 T cell ratios as well as TCR levels were also determined for lymph 
node cells. In addition to that the number of regulatory T cells (Foxp3+CD25+) was 
interesting, since they express CTLA-4 constitutively and also need it for their function. 
However all cell ratios were comparable between WT and sCTLA-4-KD lymph nodes (Figure 
14). 
 
Figure 14: FACS staining of WT and sCTLA-4 KD lymph nodes for TCR CD4, CD8, 
Foxp3 and CD25 (data: Stephan Kissler) 
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7.1.4 T cell activation in vitro 
There were no abnormalities detected in the ratios of the different T cell subsets, suggesting 
that there are probably no differences in signaling favoring one subset in sCTLA-4 KD mice. 
This phenotypic characterization did not, however, reveal whether the TCR signaling in 
general is affected.  
To clarify this, lymph node cells were firstly activated with different concentrations of anti- 
CD3 in vitro, demonstrating that WT and sCTLA-4 KD T cells proliferated to exactly the 
same extent (Figure 15). 
 
Figure 15: Proliferationassay, Thymidine incorporation measured after activation of 
lymph node cells with increasing anti-CD3 concentrations (data: Stephan 
Kissler) 
 
Subsequently I started my own work by analyzing T cell activation in more detail, by looking 
at the phosphorylation state of the proximal signal transduction protein ZAP-70. First of all 
the timecourse of ZAP70 phosphorylation following TCR activation and crosslinking was 
assessed. The concentration of anti-CD3 used was in this case 10µg/ml, which was then 
crosslinked by an anti-hamster antibody (also 10µg/ml). As already described by Houtman 
and colleagues201, the phosphorylation of ZAP-70 peaked very early (here 30 seconds) after 
activation-start. In our approach however the phosphorylation state turned out to be instable, 
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since its signal decreased already at 2 minutes of activation time and was almost gone at the 5 
minutes timepoint (Figure 16). 
 
Figure 16: Flow cytometric analysis of phospho-ZAP-70 in lymph node cells activated 
with crosslinked anti-CD3 at different periods of time in 37°C 
 
Now WT and sCTLA-4 KD lymph node cells were compared with respect to their activation 
state reflected by phospho-ZAP70 amount. Since the largest signal was seen for WT cells at 
30 seconds to 2 minutes of activation, these time points were also chosen in this experiment. 
After experiments with 5 mice for WT and sCTLA-4 KD respectively it became clear that no 
significant difference exits in this two strains concerning proximal TCR signal after anti-CD3 
activation in vitro (Figure 17). 
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Figure 17: Flow cytometric analysis of phospho-ZAP-70 in WT (n=5) and sCTLA-4 KD 
(Tg, n=5) lymph node cells activated with crosslinked anti-CD3 at different 
periods of time in 37°C (A) whole lymph nodes (B) gated on CD4+ 
 
7.1.5 Function of regulatory T cells 
In vitro proliferation of stimulated T cells was not affected by a reduced sCTLA-4 expression. 
Still CTLA-4 is not only a potent negative regulator of conventional T cells202 but also one of 
the most important effector molecules for regulatory T cells119. The next step consequently 
was to have a closer look at the function of these cells, first in vitro. 
7.1.5.1 Conventional in vitro suppression assay 
For this, a conventional suppression assay was performed, in which effector T cells (Teff) are 
cocultured with Tregs at different ratios under anti-CD3 stimulation. Figure 18 shows a 
representative result from 4 independent experiments. Especially at higher Teff / Treg ratios 
these show a reduced suppressive activity of sCTLA-4 KD regulatory T cells. This effect is 
independent of the origin of the effector T cells (WT or transgenic). 
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Figure 18: Proliferation of Teff, (A: WT, B: sCTLA-4 KD) assessed via thymidine3H 
incorporation, after 72h culture together with different amounts of WT or 
sCTLA-4 KD Tregs.  
 
7.1.5.2 Cytokine production 
Regulatory T cells inhibit or abrogate the activation of naïve T cells. Apart from proliferation, 
this can also be seen in the levels of cytokines secreted by these Teffs.  
Directly in correlation with proliferation stands the secretion of IL-2 as well as the heightened 
response to it. Along with activation of naïve T cells CD25, the IL-2 receptor alpha chain, 
gets upregulated, thereby providing a high-affinity IL-2 receptor, allowing an autocrine action 
of this cytokine. Tregs constitutively express CD25 thus acting as an IL-2 sink. 
In the in vitro setting of the suppression assay, a large proportion of Teffs differentiates into 
TH1 cells, secreting IFNγ. A reduction of this cytokine in the presence of Tregs also is an 
indication for the abrogated activation of Teffs. 
To test the ability of sCTLA-4 KD Tregs to inhibit Teff activation on the cytokine level, the 
supernatants of a classic suppression assay were tested for IL-2 and IFNγ by ELISA (Figure 
19) and CBA (data not shown, confirm ELISA results). 
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(A) (B) 
Figure 19: Cytokine levels, assessed by ELISA, in the supernatant of a representative 
suppression assay, (A) IL-2 levels, (B) IFNγ levels  
 
Consistent with the finding, concerning the suppression of proliferation, Treg cells lacking 
sCTLA-4 were defective in dampening the IFNγ production of Teff in the culture. IL-2 
inhibition however was not affected by the knockdown of sCTLA-4. 
7.1.5.3 Treg phenotype 
Since the regulatory T cells of sCTLA-4 KD mice are defective in vitro in inhibiting 
activation of conventional T cells, the question arose if the overall Treg phenotype is 
somehow altered in the transgenic animals. 
During the characterization of different cell ratios (section 7.1.3), CD25+Foxp3+ cells of WT 
and transgenic mice were seen to be the same in number and in the expression levels of these 
two markers. However there are other markers for Treg cells, like CTLA-4 and the 
glucocorticoid-induced tumor necrosis factor receptor (GITR), which are constitutively 
expressed in Tregs and upon activation also in conventional T cells, similar to CD25.  
Since CTLA-4 is predominantly present in intracellular compartements203, like the trans golgi 
network204, lysosomal vesicles205, endosomes and secretory granules206, intracellular 
expression of CTLA-4 was assessed.  
GITR and CTLA-4 expression were observed in lymph node cells, activated with 0,5 µg/ml 
anti-CD3 for five days. Figure 20 shows the expression level of intracellular CTLA-4 (A, B) 
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and GITR (C, D) in CD4+CD25- cells (A, C) and CD4+CD25+ cells (B, D) from day 0 to day 
3.  
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Figure 20: Flow cytometric analysis of intracellular CTLA-4 (A, B) and surface GITR 
(C, D) expression over four days activation in CD4+CD25+ (B, D) and 
CD4+CD25- cells (A, C); cells from WT mice (black line) or sCTLA-4 KD 
mice (filled grey histogram); for GITR staining isotype control is shown 
(grey line) 
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WT and sCTLA-4 KD lymph node cells behaved the same in respect to flCTLA-4 as well as 
GITR expression and upregulation. Expression levels on day 4 and 5 are not shown, but were 
also the same in WT and sCTLA-4 KD cells. The staining showed that the knockdown of 
sCTLA-4 apparently does not influence the expression of the full length form. 
7.1.5.4 Coculture of Treg cells with dendritic cells 
After having found out that there seems to be some defect in the function of regulatory T cells 
from mice with reduced sCTLA-4 expression, in the absence of an obvious phenotype, the 
next step was to narrow down the cause of this defect. The interaction with APCs is claimed 
to be one of the most important modes of action for Treg cells at least in vitro and recently it 
could be shown that loss of CTLA-4 in Treg cells alone affects the downregulation of 
CD80/86 on DCs119.  
 
With that background, a coculture experiment with splenic dendritic cells and regulatory T 
cells was carried out to gain information about the ability of sCTLA-4 KD Treg cells to 
downregulate CD80/86 on DCs. For this 40.000 DCs were mixed either with 150.000 Teff 
and Treg cells or Treg cells alone. The T cells were activated with 1µg/ml anti-CD3 and 
incubated with the DCs for 42 hours. Following coculture, cells were stained for CD80/86, 
CD11c and propidium iodide. Living dendritic cells, characterized by being propidium iodide 
negative and CD11c positive were then analyzed for their CD80/86 expression. Despite 
problems concerning viability of the splenic dendritic cells a downregulation of CD86 by WT 
Treg cells could be observed. Treg cells from sCTLA-4 KD mice were clearly defective in 
that ability (Figure 21 A and B). This phenomenon was even stronger when no Teff cells 
were coincubated (Figure 21 A). CD80 expression however was not seen to be differentially 
downregulated (Figure 21 C and D). The signal for CD80 on day 2 as well as the extent of 
downregulation by Treg cells was also generally lower then that of CD86. The histograms are 
representative for two independent experiments. 
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Figure 21: Expression level of CD86 (A,B) or CD80 (C,D) on DCs after coculture with 
WT Treg (grey line) or sCTLA-4 KD Treg (black line) or alone (filled grey 
histogram), without (A,C) or with (B,D) Teffs  
 
7.1.5.5 Suppressive activity of induced regulatory T cells 
There are two main subsets of Foxp3+ regulatory T cells, natural and induced Treg (iTreg) 
cells, which differ in their development. Natural Treg (nTreg) cells emerge from the thymus 
and induced Treg cells develop from conventional naïve CD4+ T cells in the periphery upon 
stimulation with TGFβ. The question that came up after having found a defect in Treg 
function and one of the possible mechanisms behind it was, if this effect is intrinsic to natural 
Treg cells and thus somehow linked to development of these cells. 
 
In order to address this question, induced Treg cells were tested for their suppressive ability. 
For this they first had to be differentiated from naïve CD4+CD62L+ T cells in vitro. The 
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optimization process revealed that 2µg of plate bound anti-CD3 (24 well plate, 0,5 x 106 cells 
per well) with 2µg soluble anti-CD28 and 2ng TGFβ gave the best yield of Foxp3+ cells after 
4 days (Figure 22). 
 
 
Figure 22: Optimization of TGFβ amount for iTreg production in vitro, 2µg anti-CD3 
plate bound, 2µg anti-CD28 
 
With these conditions Treg induction was effective and consistent so that iTregs could be 
produced (Figure 23 A) and used for a conventional suppression assay analogous to that 
already performed with natural Treg cells (section 7.1.5.1). The data concerning the Treg/Teff 
ratios was adjusted to the yield of iTreg cells in the preparation.  
Similar to the suppression assay with nTregs the induced Treg cells from sCTLA-4 KD mice 
are defective in inhibition of Teff proliferation (Figure 23 C and D). The results shown are 
representatives of three independent experiments. 
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Figure 23: (A) CD4 and Foxp3 staining of in vitro induced Treg cells, these were used 
for (B) and (C) Suppression assay iTregs, corrected to amount of Foxp3+Treg 
cells in the assay; (B) WT Teff; (C) sCTLA-4 KD Teff 
 
By this experiment it could be shown that Tregs with diminished sCTLA-4 expression are 
defective in their ability to suppress Teff activation, independent of their development and 
origin. 
7.1.6 In vivo:  influence of sCTLA-4 knockdown on autoimmunity 
In vitro experiments so far indicated a defect in regulatory T cells in sCTLA-4 KD animals. 
The goal of the study however was to evaluate whether the reduction of sCTLA-4 expression, 
would have an effect on autoimmunity in vivo.  
7.1.6.1 Suppressive Treg activity in vivo: Colitis model 
An in vivo model that had been shown to be sensitive to CTLA-4 blockade and to be 
reversible by administration of Tregs is the CD4+CD45RBhi cell induced colitis 207,208.  The 
underlying studies have not been performed on the NOD background, however another report 
showed that the adoptive transfer of CD4+CD45RBhi cells into NOD.SCID mice results 
predominantly in high colitis incidence209. Given the known CTLA-4-dependent Treg action 
in this model we concluded that this would be a reasonable setting to test the in vivo 
functionality of Tregs with disrupted sCTLA-4 expression. 
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We therefore transferred NOD.SCID mice with 4 x 105 CD4+CD45RBhi cells alone or 
together with 105 WT or sCTLA-4 KD Tregs. After 8-9 weeks colitis severity was assessed 
via histology.  Figure 24 shows the combined results of two consecutive experiments. 
 
 
Figure 24: Colitis reversal by WT and sCTLA-4 KD Tregs;  
left: Individual colitis scores of two independent experiments each group 
with n= 17-21; CD45RBhi vs. CD45RBhi+ WT Treg P = 0.045; CD45RBhi+ WT 
Treg vs. CD45RBhi+ sCTLA-4 KD Treg: P = 0.0116; CD45RBhi vs. CD45RBhi+ 
sCTLA-4 KD Treg: P = 0.83; right: representative colon histology sections 
 
The adoptive transfer of CD4+CD45RBhi cells resulted in a mild but significant colon 
inflammation. This pathology could be significantly reduced by the administration of WT 
regulatory T cells. In line with our in vitro findings we observed an abrogated sCTLA-4 KD 
Treg function that failed to inhibit the inflammation caused by CD4+CD45RBhi cells. 
Together with the in vitro data, this experiment provides further evidence for a role of 
sCTLA-4 in the function of regulatory T cells. 
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7.1.6.2 Spontaneous diabetes 
To decipher whether the correlation of sCTLA-4 splice frequency reduction with a 
susceptibility polymorphism in humans is a causal relationship, the impact of sCTLA-4 KD 
on diabetes development in NOD mice was observed. Since NOD females already have a 
high incidence of developing diabetes, we decided to also follow disease onset in the 
protected congenic strain Idd5.1 NOD, and thus also bred the sCTLA-4 shRNA onto this 
background. The rationale for choosing this congenic line was that Idd5.1 provides a 
protective CTLA-4 allele from the C57BL/10 line, with heightened liCTLA-4 expression but 
an unchanged sCTLA-4 splice variant. This allowed us to see the effect of sCTLA-4 loss in 
the environment of an otherwise unaltered, protective CTLA-4 locus.  
Over a period of approximately 200 days cohorts of NOD WT, sCTLA-4 KD, Idd5.1 WT and 
Idd5.1 sCTLA-4 KD were followed up on diabetes onset. They were tested weekly for 
glycosuria (Figure 25). 
Figure 25: Diabetes development in female cohorts of different genotype: NOD WT (n = 
40), sCTLA-4 KD (n = 83), Idd5.1 (n = 43), and Idd5.1 sCTLA-4 KD (n = 64);  
(A) diabetes incidence survival curve,  
Log-rank test: WT vs. sCTLA-4 KD P = 0.16; WT vs. Idd5.1 P < 0.0001; WT vs. 
Idd5.1 sCTLA-4 KD P = 0.0026; sCTLA-4 KD vs. Idd5.1 P = 0.0009; sCTLA-4 KD 
vs. Idd5.1 sCTLA-4 KD P = 0.0547; Idd5.1 vs. Idd5.1 sCTLA-4 KD P = 0.0893.  
(B) day of onset of all diabetic mice, lines indicate median;  
  
(A) (B) 
RESULTS 
 91 
WT n = 28; sCTLA-4 KD n = 48; Idd5.1 n = 13, Idd5.1 sCTLA-4 KD n = 28. t test: 
WT vs. sCTLA-4 KD P = 0.77; WT vs. Idd5.1 P = 0.0006; WT vs. Idd5.1 
sCTLA-4 KD P = 0.14; sCTLA-4 KD vs. Idd5.1 P = 0.0004; sCTLA-4 KD vs. 
Idd5.1 sCTLA-4 KD P = 0.16; Idd5.1 vs. Idd5.1 sCTLA-4 KD P = 0.0186. 
 
As expected no influence of the sCTLA-4 KD could be seen on the fully susceptible NOD 
background. Moreover loss of sCTLA-4 on the protected Idd5.1 background did not result in 
a significant increase of incidence (Figure 25 A). However protection conveyed by the Idd5.1 
congenic allele was completely reversed by the knockdown as to the day of onset (Figure 25 
B). This is also reflected and supported by the statistical analysis that shows a significant 
difference between the onset of diabetes in Idd5.1 and Idd5.1 sCTLA-4 KD strains, but not 
between Idd5.1 sCTLA-4 KD mice and WT or sCTLA-4 KD backgrounds.  
Loss of the sCTLA-4 splice variant was thus shown to accelerate susceptibility to diabetes. 
 
The aim of this thesis was to understand if the reduced sCTLA-4 splice variant expression 
associated with the susceptibility allele CT60 is causative for an increased risk of T1D.  
We decided to study the impact of sCTLA-4 loss in the NOD mouse model and introduced an 
shRNA directed specifically against this isoform via lentiviral transgenesis. The newly 
generated mouse line proved to be defective in sCTLA-4 expression however had no 
alterations in immune cell composition or ability of effector T cells to be activated.  
When examining the function of regulatory T cells in vitro and in vivo, we found their 
function to be clearly impaired due to the loss of sCTLA-4. The underlying mechanism could 
at least partly be attributed to the failure of sCTLA-4 KD Treg cells to modulate 
costimulation by antigen presenting cells. Furthermore we could show that loss of sCTLA-4 
renders NOD mice with an otherwise protective CTLA-4 allele more prone to diabetes. 
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7.2 Functional study of CLEC16A in T1D 
CLEC16A was identified as a susceptibility locus for several autoimmune disorders, including 
T1D. To clarify its function in the immune system and its connection with type 1 diabetes, the 
transcript was knocked down on the NOD and the C57BL/6 background.  
7.2.1 In vitro verification of Clec16a shRNA 
Thus three different shRNA sequences complementary to the murine Clec16a cDNA were 
chosen by using the described algorithm and cloned into the pLBM vector. Subsequently they 
were tested for their activity to promote RNAi in a luciferase reporter assay. Sequence #3 had 
the highest knockdown efficiency with about 85% reduction of expression and was chosen for 
the generation of transgenic animals (Figure 26).   
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Figure 26: Luciferase assay for three different shRNAs specific for Clec16a 
All vectors (pLBM-shRNA-Clec16a#1; #2 and #3) were previously cloned 
and validated by Daniela Blassfeld during her bachelor thesis in the 
laboratory. 
 
7.2.2 Generation of transgenic mice 
After sequence #3 was chosen, it was used to produce lentivirus in 293F cells. Virus 
preparations with high titers (above 108 particles/µl) were subsequently injected into NOD 
and C57B/L6 embryos. Injections resulted in founder mice with about 50% GFP expressing 
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NOD lymphocytes and 40% in C57B/L6. Expression was even higher in granulocytes. They 
were then further bred to see if the expression is stable and to obtain homozygosity. 
Homozygous NOD CLEC16A KD mice manifested 70% EGFP positive cells among 
lymphocytes and even  > 85% in B cells and granulocytes in subsequent generations. The 
EGFP expression was somewhat lower in C57BL/6 CLEC16A KD mice with 62% in 
lymphocytes and 77% in granulocytes (Figure 27). 
 
 
Figure 27:  Flow cytometric analysis of blood samples taken from offspring of two F2 
NOD and one C57BL/6 mouse derived from a breeding of CLEC16A KD 
heterozygous mice. Upper row shows negative mouse, middle row gives GFP 
expression of granulocytes and lymphocytes in a homozygous NOD 
CLEC16A KD mouse,  
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7.2.3 Knockdown examination 
The GFP expression alone does not prove the reduction of CLEC16A expression, thus the 
knockdown was to be validated.  
7.2.3.1 CLEC16A mRNA expression in transgenic mice 
Since the shRNA targets the Clec16a mRNA, we first conducted a quantitative PCR to assess 
the mRNA reduction. As the expression of CLEC16A was shown to be largely restricted to 
antigen presenting cells we reasoned to first validate the knockdown in lymphoid organs. We 
therefore extracted RNA from lymph nodes and spleens of WT and CLEC16A KD NOD 
mice and performed a qPCR based on the UPL system by Roche for Clec16a and Gapdh with 
the cDNA obtained from it. 
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Figure 28: ΔCT of Clec16a mRNA expression against Gapdh in WT and CLEC16A KD 
LN and spleen of two mice of each genotype; UPL7 for Clec16a and UPL9 
for Gapdh were used with the appropriate primer sets 
 
A slight but significant reduction of Clec16a mRNA expression in CLEC16A KD NOD could 
be observed (Figure 28). The experiment was repeated also with a different UPL/Primer set, 
however the reduction of Clec16a expression in the transgenic organs did not always reach 
significance, probably due to the small difference. 
Additionally we also tested the knockdown in sorted B and T cells. Both cell types are 
available in sufficient cell numbers in lymph nodes and spleen to perform a qPCR and 
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expression in B cells had been shown before. They were sorted at the FACS-AriaIII after 
staining for CD19 and TCRβ chain. The cDNA obtained after RNA extraction was then used 
for qPCR. 
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Figure 29: ΔCT of Clec16a mRNA expression against Gapdh in WT and Clec16a KD  
(GFP+) T and B cells of two mice of each genotype; UPL9 for Clec16a and 
Gapdh were used with the appropriate primer sets 
 
The knockdown could not be confirmed with UPL7, but by employing UPL9 with the 
suggested Clec16a Primer set (Figure 29).  
However also in the sorted B and T cells the extent of the expression difference, as already 
seen in the whole organs, is small and ranges about ½ cycle, which can be calculated to an 
mRNA expression reduction of approximately 25%. Both experiments have been performed 
on male and female mice without revealing a gender difference. 
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7.2.3.2 CLEC16A protein expression in CLEC16A KD mice 
In addition to the mRNA reduction induced by the introduced shRNA, the assumed 
consequential loss of CLEC16A protein was to be tested by Western blot. The polyclonal 
antibody directed against the human form of CLEC16A, but also reactive for the murine 
form, was kindly provided by Lucy Davison from the Lab of John Todd, Cambridge, UK. 
Also the protocol to detect this very unstable protein was developed by her. 
Since the knockdown had earlier by qPCR been indicated to be rather modest, we decided to 
perform the western blot on cells that had been sorted for GFP expression since we 
anticipated the effect to be visible there. 
 (A) (B) 
Figure 30: Protein detection after SDS-PAGE and Immunoblot of FACS sorted spleen 
cells, (A) detection with CLEC16A antibody, (B) Tubulin antibody 
 
However detection of the full length isoform of CLEC16A (117kDa) proved to be difficult 
because of the small half-life and the instability of the protein. The instability index, 
calculated with the ProtParam tool at ExPASy Proteomics Server (http://expasy.org/cgi-
bin/protparam) accounts for 54.41 for the full length isoform. A protein with a value above 40 
is considered unstable. The half-life in human cells is estimated to 1.1h. 
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Nevertheless a weak signal at around 117kDa was visible in the western blot, though no 
altered expression in the GFP+ cells from CLEC16A KD NOD mice could be detected 
(Figure 30). Additionally the antibody bound to a protein with the size of 35kDa, not 
corresponding to any of the known mCLEC16A protein isoforms.  
 
Taken together, a small reduction of mRNA expression was detected, however this could not 
be confirmed by the western blot results, probably due to instability and small half-life of the 
protein. Thus validation of the Clec16a knockdown remained inconclusive. 
 
7.2.4 Diabetes protection of CLEC16A KD mice 
Since the locus of CLEC16A is associated with human diabetes we wanted to determine its 
role in disease development in the NOD mouse and in doing so learn more about its function 
in the immune system. 
7.2.4.1 Spontaneous diabetes 
For this WT and CLEC16A KD NOD mice were monitored weekly over 200 days for 
diabetes development, by testing for glucosuria.  
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Figure 31: Diabetes development in female cohorts of different genotype; Logrank Test: 
P<0.0001 
 
RESULTS 
 98 
Surprisingly NOD CLEC16A KD mice were almost completely protected from diabetes 
development; only two out of 42 mice became diabetic during the testing period (Figure 31). 
7.2.4.2 Cyclophosphamide induced diabetes 
To further examine the protection from diabetes development of NOD CLEC16A KD mice, 
we accelerated disease onset by administration of cyclophosphamide. The chemotherapeutic 
drug preferentially targets proliferating lymphocytes and thus reduces the pool of regulatory T 
cells. It also interferes with the function of these cells and skews the T helper cell population 
towards the TH1 type due to a cytokine storm. By these mechanisms it causes a simultaneous 
onset of diabetes in NOD mice 195-198.  
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Figure 32: Diabetes development in female groups of different genotype (8-9 weeks old) 
after cyclophosphamide treatment; two independent experiments are depicted 
in one graph; Logrank Test: P<0.0001 
 
Independent of the loss of regulatory T cell function, NOD CLEC16A KD mice are still 
strongly protected from developing diabetes (Figure 32). Where NOD WT mice had a 
comparable diabetes incidence to the spontaneous form, NOD CLEC16A KD mice hardly got 
sick, also in line with spontaneous diabetes assessment. 
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7.2.4.3 CY induced diabetes in splenocyte transferred NOD.SCID mice 
The experiments so far did not give any information if the cause for the protection from 
diabetes in NOD CLEC16A KD mice lies in the immune system or in the beta cells 
themselves. To address this question, we adoptively transferred NOD.SCID mice with 
splenocytes from WT or CLEC16A KD NODs and induced diabetes with cyclophosphamide 
after the transferred cells had time to populate the peripheral lymphoid organs. The rationale 
behind this experiment was to test the ability of CLEC16A KD immune cells to protect WT 
beta cells from being destroyed. 
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Figure 33: Diabetes development in female NOD.SCID mice (10-14 weeks old) 
transferred with 107 splenocytes from either NOD WT or NOD CLEC16A 
KD females, injection of CY on day 21; Logrank test P= 0,0057 
 
The protection seen in spontaneous and CY induced diabetes could be replicated in the 
adoptive transfer setting (Figure 33). In NOD.SCIDs transferred with WT splenocytes the 
diabetes incidence even reached 100%, CLEC16A KD splenocytes conveyed the disease 
however only in one out of eight tested mice. This suggests that the protection is at least 
partly derived from an altered immune function, as CLEC16A KD splenocytes fail to destroy 
WT beta cells. Whether beta cells in CLEC16A KD mice are also altered will be more 
RESULTS 
 100 
conclusively investigated by the generation and testing of NOD.SCID CLEC16A KD mice 
that are currently being bred. 
7.2.4.4 CY induced diabetes in B and T cell transferred NOD.SCID mice 
We have shown that the protection from diabetes is due to the altered immune function in 
CLEC16A KD mice. To further narrow down the exact population that is responsible for the 
lack of diabetes development in these mice, we focused on the two most abundant cell subsets 
in the spleen, B and T cells.  
T Cells  
WT CLEC16A KD 
WT 1 2 
B Cells 
CLEC16A KD 3 4 
Table 1: Genotype combinations of B/T cell transfer into NOD.SCID mice 
 
Since we wanted to determine which one of the two subsets alone is responsible for disease 
protection, we transferred these cells in different genotype combinations (Table 1) into 
NOD.SCID mice and challenged them with CY after three weeks. Two million cells of each 
subset were transferred, after they had been negatively selected by MACS preparation. 
RESULTS 
 101 
0 5 10 15 20
0
25
50
75
100
1 (n=7)
3 (n=5)
2 (n=5)
4 (n=4)
days post CY injection  
Figure 34:  Diabetes development in female NOD.SCID mice (8 weeks old) transferred 
with T and B cells (2 x106 each) of different genotypes, combinations see 
Table 1; Logrank test of combined 1/2 vs. 3/4 : P=0.0027  
 
Transfer of B and T cells alone resulted in a similar incidence of diabetes after CY treatment, 
when comparing the purely WT and purely transgenic subset combinations (Figure 34, 1 and 
4). Notably the protection of NOD.SCID mice from developing diabetes was still apparent 
when WT B cells were cotransferred with CLEC16A KD T cells (group 2). However the 
protective effect was not seen when WT T cells were cotransferred with Clec16a KD B cells 
(group 3). Thus a significant difference in diabetes development is observable, depending on 
the origin of the transferred T cells (groups 1 and 2 versus 3 and 4). 
7.2.5 T cell characterization  
In vivo adoptive transfer experiments had revealed that the diabetes protection we could 
observe in Clec16a KD mice could be T cell inherent. Consequently we examined T cell 
function in vitro to detect possible alterations that could be causative to this observation. Most 
of the following in vitro experiments were performed by or together with Lilli Teresa Probst 
in the course of her doctoral thesis. 
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7.2.5.1 T cell proliferation 
For initial evaluation of the proliferative ability, CD4+CD25- T effector cells derived from 
WT NOD or Clec16a KD NOD lymph nodes and spleen, were activated with anti-CD3 and 
antigen presenting cells, also from different genotypes. 
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Figure 35: H3-Thymidin uptake of 25.000 CD4+CD25- T cells activated for 3 days with 
1µg/ml anti-CD3 on 3 x 105 WT APCs (A) or Clec16a APCs (B); both 
figures show combined results from four independent experiments; data 
provided by Lilli Teresa Probst 
 
Both WT and Clec16a KD T cells proliferated upon stimulation with anti-CD3 and APCs. 
However Clec16a KD T cells were clearly hampered in their proliferative activity on both 
APCs (Figure 35).  This also held true for other anti-CD3 concentrations, as seen in dose 
response experiments conducted by Lilli Teresa Probst (data not shown). 
 
A second way to assess the proliferative capacity of Clec16a KD T cells was the mixed 
lymphocyte reaction. In this assay T cells that recognize allogeneic MHC are activated and 
proliferate. This happens without addition of anti-CD3, thus displaying the capability of an 
allo-reactive subset, accounting for 5-10% of total T cell repertoire, to get activated by TCR-
MHC contact. 
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Figure 36: H3-Thymidin uptake of splenocytes after 3 days incubation with respective 
APCs (irradiated splenocytes), graph is a summary of three independent 
experiments, data provided by Lilli Teresa Probst 
 
Surprisingly, unlike in the anti-CD3 / APC induced proliferation, the mixed lymphocyte 
reaction showed a strong proliferation of CLEC16A KD allo-reactive T cells (Figure 36), 
although only a small fraction of T cells would be activated in this setting. However no 
separation of CD4 and CD8 T cells had preceded this assay, so the subset of the proliferating 
T cells could not be distinguished. This suggests that in principle CLEC16A KD Tcells have 
the ability to respond to certain stimuli similarly to WT cells. 
 
To further elucidate the disadvantage of CLEC16A KD T cells on stimulation with anti-CD3 
and WT APCs, we chose two alternative means of activating the T cells without the use of 
APCs. On the one hand we employed anti-CD3 and anti-CD28 coupled beads (Invitrogen) as 
a strong stimulator, both giving first and second signal. On the other hand we overrode the 
necessity to stimulate via the TCR, by adding PMA/Ionomycin to the cells, which directly 
activates the PKCθ /Ca2+ dependent signal transduction. 
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Figure 37:  H3-Thymidin uptake of 25.000 CD4 T cells activated for 3 days with anti- 
CD3/anti-CD28 covered beads or PMA/Ionomycin, data provided by Lilli 
Teresa Probst 
 
In line with the previous anti-CD3 mediated CD4 T cell proliferation assay, CLEC16A KD T 
cells proliferated significantly less, when activated with antibody-coated beads, compared to 
WT T cells. However this effect was completely lost in the setting of targeting the signal 
transduction pathway further downstream, as by PMA/Ionomycin (Figure 37). 
7.2.6 Characterization of Antigen Presenting Cells 
Adoptive transfer experiments (7.2.4.4) as well as in vitro T cell proliferation assays (7.2.5) 
clearly showed a defective T cell function in CLEC16A KD mice that leads to protection 
from diabetes. However since CLEC16A has been shown to be expressed in antigen 
presenting cells151 and the Drosophila orthologue being crucial for the maturation of 
endosomes160 we hypothesized a defect in APCs due to the knockdown could be altering T 
cell function. 
7.2.6.1 Activation of peripheral APCs 
In order to test this hypothesis we proceeded with assessing the in vitro functionality of 
antigen presenting cells. Most experiments were conducted by Lilli Teresa Probst and are in 
greater detail described in her doctoral thesis. We commenced this assessment by activating 
NOD WT and CLEC16A KD B cells and dendritic cells (DCs) with lipopolysaccharide (LPS) 
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or anti-CD40 and looked for upregulation of T cell stimulatory molecules, that if altered 
could be causal for the lack of responsiveness of CLEC16A KD T cells. 
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Figure 38:  Upregulation of CD86 and MHC in LPS or anti-CD40 stimulated B cells; 
cells were activated for one or three days with different concentrations of 
LPS or anti-CD40, concentrations are given in µg/ml, CD86 and MHC were 
measured by FACS staining, median fluorescent intensities are shown; (A), 
(C) and (E) show measurements after LPS stimulation; (B), (D) and (F) 
measurements after anti-CD40 stimulations; (A) and (B): CD86 level; (C) 
and (D): extracellular MHCII level; (E) and (F) intracellular MHCII level 
 
Activation in both NOD WT and CLEC16A KD B cells with respect to upregulation of CD86 
and MHCII was comparable (Figure 38). Data obtained with dendritic cells is not shown in 
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this thesis, however it did not display any altered function in CLEC16A KD cells either. This 
information as well as data about proliferation, upregulation of PDL-1 /2, CD54, GITR-L and 
CD40 can be found in Lilli Teresa Probst´s doctoral thesis. These additional data again did 
not reveal any difference between NOD WT and CLEC16A KD antigen presenting cells. 
 
As already mentioned above, the very conserved Drosophila orthologue ema had been shown 
to be important for endosomal maturation160, therefore we decided to test endosomal uptake 
and processing in CLEC16A KD macrophages. These were obtained by peritoneal lavage and 
after activation by culturing on tissue plates, fed with fluorescently labeled E.coli (pHrodo™, 
Invitrogen). The pHrodo™ SE dye does not give a fluorescent signal at pH 7 or higher, 
equating the extracellular pH value, thus rendering quenching unnecessary. Only upon 
acidification, as it takes place in maturing endosomes, can a fluorescent signal in the PE 
channel be detected, this signal growing stronger the lower the pH gets. This dye allowed us 
to examine the time course of antigen uptake and processing in NOD WT and CLEC16A KD 
macrophages. 
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Figure 39: pHrodo™  labeled E.coli uptake and processing time course; CLEC16A KD 
macrophages were sorted by GFP expression prior to the experiment; shown 
is the geometric mean fluorescent intensity of pHrodo, representative of three 
comparable experiments 
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Again in this experiment that was designed to shed light on endosomal processes in antigen 
presenting cells, no defect in CLEC16A KD cells could be detected. Both WT and CLEC16A 
KD macrophages took up the labeled E.coli particles and processed them in a comparable 
way that could be observed by increase of fluorescent intensity over time indicating an 
acidification of endosomes (Figure 39). 
7.2.6.2 Characterization of thymic epithelial cells 
Since no obvious defect in CLEC16A KD peripheral APCs was detected, we next turned to 
essential antigen presenting cells in the thymus, the thymic epithelial cells (TECs). There are 
two types of thymic epithelial cells important for T cell development, the cortical and 
medullary cells. Cortical TECs (cTECs) are considered mainly responsible for positive 
selection210, medullary TECs (mTECs) for negative selection. Defects in one of these or both 
could alter selection of T cells and thus render them less reactive as we have observed in 
CLEC16A KD mice. 
To determine number and activation status of TECs in NOD WT and CLEC16A KD thymi, 
these first had to be digested by collagenases. Then epithelial cells were separated from 
thymocytes by running a Percoll gradient. cTECs and mTECs are identified in the epithelial 
cell fraction by an antibody staining for CD45- EPCAM+MHCII+Ly51+ or Ly51- respectively 
(Figure 40). 
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Figure 40: Gating strategy for cTEC/mTEC staining; TEC fraction after Percoll 
gradient, was first gated on CD45-, then on EPCAM+, cTEC/mTEC subsets 
were distinguished by Ly51 expression; lower row shows CD45 expression 
of thymocyte fraction after Percoll gradient and GFP expression of CD45- 
EPCAM+ cells 
 
To also assess activation status and ability to provide costimulation to developing T cells, 
expression levels of CD86 and CD80 were measured along with the flow cytometry analysis. 
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Figure 41: cTEC and mTEC proportions in (A) NOD WT and (B) NOD CLEC16A KD 
thymi, (C) summarizes six independent experiments P=0,0391; (D) to (I) 
summarize five independent experiments, geometric mean fluorescent 
intensities are given; (D) MHCII level of cTECs, P=0,0207; (E) CD80 level 
of cTECs, not significant (ns); (F) CD86 level of cTECs, ns; (G) MHCII 
level of mTECs; (H) CD80 level of mTECs; (I) CD86 level of mTECs, 
P=0,0247 
 
The staining for TECs revealed that in CLEC16A KD thymi the cTEC compartment was 
clearly and significantly enlarged. Additionally a significant higher expression of MHCII and 
tendency to higher CD80/86 expression were featured by this CLEC16A KD cTEC subset 
(Figure 41). Costimulatory molecule and MHCII expression in mTECs did not differ to that 
extent between NOD WT and CLEC16A KD thymi, however a significantly higher CD86 
expression could be seen. 
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7.2.6.3 Analysis of the TCR repertoire 
As cTECs are crucial for positive selection and alterations in antigen processing in these cells 
can have effects on single TCR specifities33 we decided to analyze the TCR repertoire of 
CLEC16A KD NOD mice. For this we compared abundance of ten different Vβ chains in 
splenocytes and thymocytes of NOD WT and NOD CLEC16A KD mice by flow cytometry. 
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Figure 42: Flow cytometric analysis of distribution of ten Vβ chains in NOD WT 
(black) and NOD CLEC16A KD (white) CD4+ CD25- (A), CD4+ CD25+ (B), 
RESULTS 
 111 
CD8+ splenocytes (C) and CD4 SP (D) or CD8 SP thymocytes (E); combined 
results of six different mice for splenocytes and five for thymocytes 
 
Analysis of these ten specific Vβ chains however did not reveal any difference in thymic 
selection of these specifities (Figure 42). 
 
In this report it was shown that NOD CLEC16A KD mice are clearly protected from diabetes 
development. The origin of this protection could be narrowed to the T cell compartment, 
which was found to be hyporeactive in vitro. Analysis of antigen presenting cells revealed an 
enlarged and activated cTEC compartment, suggesting a possible alteration in the thymic 
selection of T cells in CLEC16A KD mice. 
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8 Discussion and Outlook 
8.1 Functional study of sCTLA-4 
Genome association studies showed that a polymorphism in the CTLA4 gene conveys 
susceptibility to T1D.147 The susceptibility SNP was correlated with reduced expression of the 
splice isoform sCTLA-4148.  
To date there is no information about the differential functions of CTLA-4 isoforms. A lot of 
the knowledge that is now available about CTLA-4 function is based on studies on CTLA-4 
knockout mice. However these mice lack exon 2 and part of exon 3202, affecting all three 
isoforms present in mice. With these mice a differentiated examination of the isoforms is thus 
impossible. 
With our approach we intended to target sCTLA-4 alone by RNAi, mimicking its human T1D 
susceptibility expression pattern and therewith studying its function in the immune system 
and T1D. To provide a genetic background generally vulnerable to T1D development, the 
knockdown was done on the NOD background.  
 
At the begin of my studies, sCTLA-4 knockdown mice with 70% knockdown efficiency 
(Figure 10) had already been generated by Stephan Kissler. Expression of the transgene 
(shRNA plus EGFP) could be detected in approximately 65-75% of lymphocytes (Figure 9). 
This effect is due to the variability of transgene expression. Since the site of integration is 
largely random with the use of lentiviral vectors, the possibility of epigenetic modification 
and silencing cannot be excluded211. This is also an explanation for the different percentages 
of EGFP in different cell subsets212.  
 
Though CTLA-4 knockout animals show a massive lymphoproliferation, which goes along 
with skewing cell ratios towards CD4+ subsets200, this is not the case if sCTLA-4 is 
selectively reduced (Figure 11,12). There is also no increase in activated T cells (Figure 13) 
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or alteration in responsiveness to TCR signaling (Figure 15, 16, 17), although CTLA-4 is 
considered to be a potent negative regulator of conventional T cells202. Especially during the 
activation of lymph node cells with anti-CD3, CTLA-4 is thought to be able to inhibit the 
costimulation by competition with CD28 for CD80/86 binding213, disruption of CD28 and/or 
TCR localization in the immunological synapse214,215, negative effects on the cell cycle216,217 
or also downregulation of CD80/86119,120. Still the reduction of sCTLA-4 does not seem to 
affect these mechanisms in such extend that it would influence the outcome of this strong 
activation by anti-CD3 (Figure 15). In line with that finding is the consistency of GITR and 
overall surface and intracellular CTLA-4 expression of Treg and Teff cells. These results 
suggest that the general phenotype of these cells is largely unaffected by the reduction of 
sCTLA-4 expression (Figure 20). 
 
CTLA-4 is also supposed to be mainly active in Treg cells, since it may be one of their most 
important modes of action119,207,208,218-221.  In conventional Treg assays (unlike in vivo), as 
performed here, cell-cell-contact is essential for mediating inhibition, though it may be 
sufficient to provide it at the initial phase of the culture111. 
 At high ratios of Treg/Teff, Treg cells with less sCTLA-4 were working as well as WT Treg 
cells. However when Treg cells were further diluted, to a degree where inhibition becomes 
weaker, they failed to mediate suppression (Figure 18).  
This finding was further supported by the fact that sCTLA-4 KD Treg cells were unable to 
suppress IFN-γ production at these ratios. As anticipated, the level of IL-2 was not dependent 
on the Treg genotype, since it is mostly reduced by the presence of the high affinity receptor 
CD25, that was not altered by the knockdown (Figure 19). 
These results gained further impact after repeating them with in vitro differentiated Treg cells, 
showing that the outcome of sCTLA-4 reduction is independent of Treg development (Figure 
23).   
Whether this is due to a reduced expression of cell-contact mediating surface-molecules or to 
a shortage in soluble mediators of inhibition, potentially sCTLA-4 itself, remains elusive. Yet 
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from the impairment at low ratios it can be inferred that there is either a mechanism affected, 
which comes into action when direct inhibition through cell contact has become impossible, 
or that the threshold of the common mechanism is marked up by reduction of sCTLA-4. 
 
To further clarify the cause for the Treg impairment, we examined one of the modes of action 
found to be dependent on CTLA-4 expression in more detail. As already mentioned, Treg 
cells were found to be able to downregulate CD80/86 on APCs, by an as yet incompletely 
clarified mechanism116-118. Recently Qureshi et al.120 showed that flCTLA-4 depletes CD80/86 
from the surface of APCs by transendocytosis. However the contribution of other CTLA-4 
isoforms were not addressed in this study.  
Coculture experiments with DCs and Treg cells revealed the necessity for sCTLA-4 in this 
mechanism, since transgenic Treg cells were heavily impaired in their inhibitory function 
(Figure 21).   
It was only possible to show this for CD86 but not CD80, because in the majority of 
experiments there was no sufficient upregulation of this costimulator in splenic DCs after 
42h. This is consistent with findings concerning the temporal expression pattern of CD80/86, 
with CD86 being constitutively expressed on T cells and APCs and CD80 being induced after 
T-cell/APC contact, with its peak after 48h of activation222.  
Thus we could show that sCTLA-4 is involved in the modulation of costimulation by splenic 
dendritic cells, thereby suggesting a possible pathway in Treg cells in which sCTLA-4 is at 
least partly effectual. These results also closely resemble the defects demonstrated by Wing et 
al.119 when conditionally knocking out CTLA-4 in Foxp3 expressing cells. Whether this is 
also the mechanism responsible for our findings in the conventional Treg assay remains to be 
clarified. 
 
Mechanisms of inhibition by Treg cells are claimed to be different in vitro and in vivo104. 
However it is not yet clear if the mechanism we revealed to be defective in sCTLA-4 KD 
Treg cells is also important in vivo. The aim of this study being to clarify the role of sCTLA-4 
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in vivo, we strived to evaluate the in vitro finding of impaired sCTLA-4 KD Treg cells in an 
in vivo model.  
Since CTLA-4 on Treg cells had been shown by Read et al.207,208 to be crucial in the 
CD4+CD45RBhi induced Colitis model, we set out to test the ability of sCTLA-4 KD Treg 
cells to protect in this setting. Due to the use of the NOD strain instead of the more commonly 
used BALB/c strain for colitis induction, overall disease severity was less pronounced than 
seen by Read et al.207,208. Nevertheless Treg cells with silenced sCTLA-4 failed to protect 
from colitis development, consistent with our in vitro data (Figure 24). A reduction of 
sCTLA-4 thus shows a comparable outcome to antibody mediated CTLA-4 blockade by Read 
et al.208. These results demonstrate a notable role of sCTLA-4 in Treg cell function also in 
vivo. 
 
The T1D susceptibility allele of CTLA-4 causes a shift in splicing ratios towards the full 
length CTLA-4 variant, thereby reducing the relative amount of sCTLA-4. Whether this 
reduction is causative to conveying susceptibility was to be ascertained in this thesis.  
Cohorts of WT NOD, sCTLA-4 KD NOD as well as Idd5.1 WT and Idd5.1 sCTLA-4 KD 
mice were therefore monitored for diabetes onset and incidence. Following diabetes 
development also on the Idd5.1 congenic background facilitated examining the effect of the 
sCTLA-4 KD on an otherwise protective CTLA-4 locus223,224. Indeed, sCTLA-4 silencing 
only transferred additional susceptibility to diabetes on the Idd5.1 background (Figure 25). 
This approach avoided a potentially confounding effect of the reduced expression levels of 
the liCTLA-4 splice variant in the fully susceptible NOD strain that was likely to render 
memory/effector T cells more receptive to initial activation by weaker stimuli224.  
Of note, the liCTLA-4 splice variant is not produced from the human CTLA-4 gene148, 
indicating that the role of sCTLA-4 may even be more prominent in humans, being the only 
other splice variant apart from flCTLA-4. 
 
DISCUSSION 
 116 
CTLA-4 had been shown to be essential to Treg cells in preventing autoimmune diseases in 
multiple studies207,208,219-221, however no discrimination between splice variants had been 
addressed. We have now shown that sCTLA-4 plays a role in Treg cell function in vitro and 
in vivo, and that it also conveys protection in the setting of autoimmune diabetes in the NOD 
model. Thus the reduction of sCTLA-4 correlated with the susceptibility allele of the locus 
CT60 is likely to be responsible for conveying higher odds to developing T1D. The 
underlying mechanism may partly be cell extrinsic in acting on antigen presenting cells, 
however the relative contribution of flCTLA-4 and sCTLA-4 in this mode of action still 
remains to be clarified.  
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8.2 Functional study of CLEC16A in T1D 
CLEC16A was found to be associated with several autoimmune diseases, with 
T1D143,151,153,225,226 and multiple sclerosis227,228 in particular. To date its function remains 
absolutely elusive. From expression analysis (BioGPS.org) the putative function could be 
linked to the immune system, (DC, B cells, NK cells) in concordance with its association with 
autoimmune diseases. Its predicted ITAM motif also contributes to that notion151. 
Furthermore a study on the Drosophila orthologue ema indicated a possible role of CLEC16A 
in endosomal maturation160.  
 
The aim of this study was the functional analysis of CLEC16A, especially in the setting of 
type 1 diabetes. To achieve this goal, we introduced an shRNA targeting Clec16a, previously 
validated in vitro (Figure 26), into NOD embryos. This was accomplished by injecting the 
embryos with lentivirus carrying the shRNA. To allow for the flexibility of including studies 
with transgenic TCR mouse lines, many of which are on the C57BL/6 background, we later 
also integrated the same shRNA into the C57BL/6 mouse line. However only few 
experiments have been conducted with this second mouse line so far. 
Both virus injections were successful as they yielded founder mice with substantial EGFP 
expression. Since the transferred shRNA was coupled to the EGFP sequence, this was an 
indirect proof of shRNA transfer to these mice. Further breeding subsequently led to 
homozygous mouse lines with improved and consistent EGFP expression levels, also 
indicating that a single copy of the construct had integrated into each mouse line. Otherwise a 
larger variety of EGFP expression would be expected, due to segregation. The EGFP 
expression of 70% in NOD and 62% in C57BL/6 lymphocytes can be attributed to the site of 
integration, as has been addressed in 8.1.  Notably the expression of EGFP was higher in 
granulocytes, 85% in NOD and 77% in C57BL/6, which was beneficial as CLEC16A had 
been hypothesized to be active in antigen presenting cells especially (Figure 27).  
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As previously mentioned, EGFP expression can only provide indirect evidence for the 
presence and effectiveness of the shRNA. A direct read-out of RNAi induced by the shRNA 
is possible by mRNA quantitation by qPCR or protein quantitation via western blotting. Both 
methods were applied in this thesis to gain insight to knockdown efficiency in the NOD-
CLEC16A KD mouse line.  
ShRNA #3 that was used to generate NOD CLEC16A KD mice aligns with a sequence in 
exon 19 of murine Clec16a. This exon is included in nine of eleven splice variants, two of 
which are non coding and one other that is predicted to undergo nonsense mediated decay 
(Ensembl). Only one putative coding mRNA, a truncated splice variant of 356bp, is not 
targeted by this shRNA, CLEC16A-006. To obtain information about the effect of the 
shRNA, firstly a qPCR based on the Universal Probe Library (Roche) was conducted, 
applying various probe and primer sets. One of these primer sets (UPL7) directly amplified 
the region that was complementary to the shRNA. However all these efforts did only reveal a 
minor knockdown of about 25% (Figure 28, 29). A high basal expression of non-coding 
mRNAs not seen in the expression analysis (BioGPS) could give an explanation. On the one 
hand the shRNA could be captured by these overexpressed mRNAs. On the other hand this 
would also explain the very high expression level of Clec16a in T cells that was very 
comparable to B cells but was not implied in the BioGPS analysis.  However through 
personal communication with Lucy Davidson from the Lab of John Todd, Cambridge (UK), 
we learned that the knockout of Clec16a could also not be confirmed adequately by qPCR. 
This would rather imply the presence of a pseudogene that was not targeted by the knockout 
and thus still gives a qPCR signal after the knockout had been accomplished. This alternative 
would also explain the lack of knockdown efficiency detected by qPCR and not exclude the 
possibility that the knockdown is higher in reality. 
 
To rule out the possibilities of pseudogenes or non-coding variants interfering with qPCR, we 
carried out western blot experiments for CLEC16A on organs and EGFP sorted splenocytes. 
The polyclonal antibody used here was directed against the human protein of CLEC16A. As 
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mentioned in the results section the protein is very unstable and has a relatively short half-life. 
Consequently only mild signals could be obtained from western blotting for the full length 
isoform (117kDa, Figure 30). However these mild signals did not reveal a reduction of 
CLEC16A in knockdown cells. Curiously the bands appearing in western blot do not match 
the predicted protein weights of the different isoforms of CLEC16A, they are rather due to 
nonspecific binding. Hence the knockdown could also not be proved by western blot, 
however also this technique failed to convincingly prove the contrary. We therefore decided 
to create an additional NOD-CLEC16A KD mouse line with another shRNA, to be able to 
confirm results obtained from the first mouse line and thus circumvent the need of showing 
the knockdown on the molecular level. An effective shRNA has now been cloned into an 
improved vector  (pUGM) and the first NOD embryos have been microinjected with 
lentivirus generated from this new vector.  
 
We then evaluated the effect of the presumed loss of CLEC16A in NOD mice and its 
influence on disease incidence. On this matter we followed cohorts of NOD WT and NOD 
CLEC16AKD females for 200 days as to glycosuria occurrence. Surprisingly, almost no 
NOD CLEC16A KD mice became diabetic, indicating a strong protection due to CLEC16A 
KD (Figure 31).  
Comparable protection could also be seen when inducing diabetes by cyclophosphamide 
administration (Figure 32). As part of its action CY causes the death of fast proliferating 
lymphocytes, thereby significantly diminishing the pool of peripheral B and Treg cells198. 
Since this depletion takes part between d2 and d7 after administration198 and diabetes onset 
takes place soon after, an acute role for peripheral B cells and Treg cells in the protection 
conveyed by knockdown of CLEC16A seems improbable. 
Expression pattern and the putative ITAM motif pointed to a role of CLEC16A in the 
immune system. We used adoptive transfer experiments to assess whether the protective 
effect of CLEC16A KD was intrinsic to the immune system, as expected. Splenocytes were 
transferred into NOD.SCID mice and diabetes was then induced by cyclophosphamide 
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administration. As foreseen, splenocytes of NOD CLEC16A KD mice were unable to transfer 
diabetes susceptibility to NOD.SCID animals, thereby excluding a beta-cell intrinsic effect 
(Figure 33). However to obviate a role of CLEC16A in beta-cells, the experiment would have 
to be repeated with transfer of NOD WT splenocytes into NOD.SCID CLEC16A KD mice. 
These mice are currently being bred and the first mice homozygous for both the transgene and 
the SCID mutation are were born and are being mated to establish the new mouse line.  
To further determine which cell subset could be responsible for diabetes protection we 
repeated the previous experiment with purified B and T cells in different genotype 
combinations. We thereby established that diabetes susceptibility was dependent on the 
genotype of T cells alone, independently of whether WT or CLEC16A KD B cells were used 
(Figure 34). Even though we initially hypothesized a role for CLEC16A in antigen presenting 
cells this finding was not entirely surprising, since T cells are the crucial cell type responsible 
for beta cell destruction and they are considerably influenced by peripheral and/or central 
APCs in their reactivity.  
 
All in vivo data led us to draw the conclusion that CLEC16A KD rendered T cells less 
autoreactive. We subsequently tested this implication in several in vitro assays.  
Indeed all efforts that were designed to activate CLEC16A KD CD4 T effector cells via 
antibody stimulation of CD3 and CD28 revealed the diminished reactivity of these cells. This 
held true regardless of the origin of APCs they were stimulated with (Figure 35), also 
contributing to the notion that APC genotype may not be crucial in the acute phase of 
activation, as already mentioned in conjunction with the CY experiments with regards to B 
cells. 
CD4 T effector cells are however in principle able to react to activation by proliferation, as 
seen after PMA/Ionomycin treatment. This indicates a defect or down tuning of signal 
transduction upstream of PKCθ activation and Ca2+ release, as these are the steps of the 
signaling chain whereupon PMA/Ionomycin acts (Figure 37). Notably CD4 T effector cells 
did not show a typical anergic phenotype (data not shown) as to CTLA-4 expression229. 
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Also, mixed lymphocyte reactions that only activate 5-10% of allo-reactive T cells did not 
show a reduced responsiveness of CLEC16A KD T cells (Figure 36). However in this assay 
full splenocytes were used as responder cells, so discrimination of CD4 and CD8 T cell 
response was not possible. Thus CD8 T cell response might mask the lack of proliferation of 
CD4 T effector cells. Another explanation could be a faster time course of this reaction to 
conventional proliferation assays that would give CLEC16A KD T cells the time to catch up. 
Time course experiments could clarify this issue. 
 
From in vivo and in vitro experiments, as well as from information about the expression 
pattern and function of the Drosophila orthologue of Clec16a we hypothesized a role of this 
gene in central or peripheral antigen presenting cells. Alterations in their ability to present 
pMHC complexes to T cells are likely to change their ability to react to stimulation. As a 
consequence we first examined peripheral APCs as to their ability of being activated 
themselves, measured by surface marker expression and by their endocytotic capacity. 
Endosomal maturation was of special interest, since the Drosophila orthologue ema is crucial 
for endosomes to develop normally. However none of the assays performed revealed any 
difference due to knockdown of Clec16a. More detailed information on this is given in the 
doctoral thesis of Lilli Teresa Probst. 
Other candidates for altered antigen presenting cells are central, thymic APCs like medullary 
and cortical epithelial cells (mTECs and cTECs). These cells are mainly responsible for 
negative and positive selection respectively and can thus influence the overall reactivity of T 
cells by selecting a certain range of TCR affinities. To gain more insight into the TECs of 
CLEC16A KD mice, we performed antibody staining of enriched thymic epithelial cells and 
analyzed them via flow cytometry. Subset staining revealed an increased cTEC compartment 
in CLEC16A KD thymi. We also found higher expression of the costimulatory molecules 
CD80 and CD86 on these cells that additionally exhibited a very high EGFP expression 
(Figure 41). This heightened EGFP intensity could point to an especially high shRNA level 
und thus higher knockdown efficiency in these cells. Of note, an EGFP dependent activation 
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effect can be dismissed, since Nishikawa et al. have previously shown that GFP expression in 
cTECs and or mTECs does not enhance cell subset ratios or activation status230. Medullary as 
well as cortical TECs have been shown to be able to stimulate T cell proliferation and to 
express costimulatory molecules, yet only a small fraction of cTECs was seen to express 
CD80 and CD86231. This specific subset is thus likely to be expanded in NOD CLEC16A KD 
mice. The increased cell number of cTECs and their heightened expression of costimulatory 
molecules points towards an alteration of positive selection in NOD CLEC16A KD mice. 
This could also provide an explanation for the impaired reactivity of T cells from these mice 
in vitro and in vivo. Nevertheless more information has to be obtained to support this notion. 
It had been shown that alterations in the proteolytic processing of proteins in the endocytic 
and lysosomal compartments can result in a diminished CD4 population29 or also in the 
abrogation of positive selection of certain TCR specifities33. As the CD4 compartment as such 
was not reduced, we had a closer look at TCR Vβ chain distribution in those mice. In the ten 
Vβ chains that were tested no difference emerged (Figure 42), not out ruling out however that 
other Vβ chains could be affected.  
 
To further investigate the outcome of CLEC16A KD on T cell selection we plan to also take 
advantage of the aforementioned NOD.SCID CLEC16A KD mice that are currently being 
bred. Bone marrow transfer of NOD WT cells into lethally irradiated NOD.SCID CLEC16A 
KD mice will give us the opportunity to follow CLEC16A sufficient T cells in their 
development through a CLEC16A deficient thymus and examine the effects of developing in 
this environment. 
 
In summary, we generated NOD mice carrying a knockdown for CLEC16A to study its 
function especially on the background of type 1 diabetes, thereby seeking to clarify the reason 
for its association with autoimmune diabetes and other autoimmune diseases. These 
knockdown animals emerged to be highly protected from diabetes. This protection could 
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subsequently be pinpointed to be caused by a defect in T cell function evidenced by 
hyporesponsiveness to TCR stimuli in vitro. Due to its reported expression pattern and a 
study that showed a role in endosomal maturation of its Drosophila orthologue, we 
hypothesized the impaired T cell reactivity to be caused by APCs. Peripheral APCs did 
however not show any alterations due to CLEC16A KD. Though when examining thymic 
epithelial cells, we found an increased cTEC pool that also featured high expression of 
costimulatory molecules, pointing towards a role of CLEC16A in T cell development. Yet 
further studies have to be conducted to gain more insight into the mechanism in which 
CLEC16A is involved. Furthermore, all key experiments will be repeated with a second NOD 
CLEC16A KD line carrying a distinct shRNA against CLEC16A that is currently being 
generated, to exclude non-specific effects and support the specificity and efficiency of the 
knockdown, especially since this could not be achieved by molecular methods. In conclusion, 
we gained the first evidence about the function of an as yet unstudied gene in the course of 
this thesis, and linked this gene’s function to the immune system, thereby providing a first 
possible causation for its association with autoimmune diseases.  
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9 Abbreviations 
APC  antigen presenting cell 
B6  C57BL/6J 
CD  cluster of differentiation/designation 
CLEC16A C-type lectin domain family 16 member a 
cTEC  cortical thymic epithelial cell 
CBA  cytometric bead array 
CTLA-4 cytotoxic t-lymphocyte antigen 4 
CY  cyclophosphamide 
DC  dendritic cell 
DMEM  Dulbecco's modified Eagle medium 
DN  double negative 
DNA  deoxyribonucleic acid 
DP  double positve 
EGFP  enhanced green fluorescent protein 
ELISA  enzyme-linked immunosorbent assay 
ema  endosomal maturation defective 
FACS  fluorescent activated cell sorting 
flCTLA-4 full length cytotoxic t-lymphocyte antigen 4 
Foxp3  forkhead box P3 
GFP  green fluorescent protein 
GITR  glucocorticoid-induced tumor necrosis factor receptor 
Idd  insulin dependent diabetes 
IFN  interferon 
IL  interleukin 
ITAM  immunoreceptor tyrosine-based activation motif 
iTreg  induced Treg 
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KD  knockdown 
KIAA0350 KI stands for “Kazusa DNA Research Institute”; “AA” are reference 
characters 
KO knockout 
liCTLA-4 ligand independent cytotoxic t-lymphocyte antigen 4 
LPS  lipopolysaccharide 
LTR  long terminal repeat 
MACS  magnetic cell separation 
MHC  major histocompatibility complex 
miRNA  micro RNA 
mTEC  medullary thymic epithelial cell 
NK cell  natural killer cell 
NOD  non obese diabetic  
nTreg  natural occurring Treg 
PCR  polymerase chain reaction 
PMA  phorbol 12-myristate 13-acetate 
pMHC  peptide / MHC complex 
qPCR  quantitative PCR 
RNA  ribonucleic acid 
RNAi  RNA interference 
RPMI-1640 Roswell Park Memorial Institute cell culture medium 
SCID  severe combined immunodeficiency 
sCTLA-4 soluble cytotoxic t-lymphocyte antigen 4 
shRNA  short hairpin RNA 
siRNA  short interfering RNA 
SNP  single nucleotide polymorphism 
T1D  type 1 diabetes 
TEC  thymic epithelial cell 
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TCR  T cell receptor 
Teff  effector T cell 
Tg  transgene 
TRA  tissue restricted antigen 
Treg  regulatory T cell 
WT  wildtype 
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